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1. Introduction  
1.1. Smoking-related epidemiology 
Smoking is the most preventable cause of mortality worldwide and is associated with 
numerous diseases, mainly chronic obstructive pulmonary disease (COPD), coronary 
heart disease, infection, cancer, stroke, gastroduodenal ulcers and peripheral vascular 
disease (Fagerström, 2002, Perez-Warnisher et al., 2019, Shaik et al., 2016, Ahluwalia et 
al., 2018). Meanwhile, there are still many non-smokers who are insidiously and 
passively exposed to second-hand smoke that could also cause various health problems 
(Tsai et al., 2018). The average life expectancy of smokers is at least 10 years shorter 
than that of non-smokers (Kalkhoran et al., 2018, Jamrozik, 2004, West, 2017, Lee et al., 
2012, Jha et al., 2013). Furthermore, approximately 6 million people die from smoking, 
many of which are youngsters (Fagerström, 2002, Edwards, 2004, Perez-Warnisher et al., 
2019, Shaik et al., 2016, West, 2017, Lee et al., 2012, Davis et al., 2007, Zarocostas, 
2009). Contemporary forecasts imply that the number of smokers worldwide will reach 
up to 1.6 billion people in the next 25 years, which means an increase in the number of 
deaths due to smoking (Perez-Warnisher et al., 2019). As a result, the number of deaths 
due to smoking will exceed the sum of deaths caused by other diseases such as 
tuberculosis, maternal deaths, automobile accidents, AIDS, suicide and homicide (Jamal 
et al., 2015). However, in that period, developing countries will contribute nearly 70% of 
smoking deaths (Edwards, 2004, Jamrozik, 2004).  
Nowadays, there is a declining trend in developed countries, while smoking rates in 
developing countries are rising (Galanti, 2008, Kalkhoran et al., 2018, Jha et al., 2006). 
Actually, smoking rates squint towards people with the lowest levels of income and 
education and concomitant mental disorder or substance abuse disorder (Kalkhoran et al., 
2018, Perez-Warnisher et al., 2019). A total of 80% of the world’s smokers are from 
middle-income countries (Health and Services, 2004, Control and Prevention, 1993). 
About 23% of adults globally, including more than 1 billion men and 250 million women, 
consume tobacco products today (Perez-Warnisher et al., 2019). Generally speaking, 
mortality in smokers is three to four times higher than in non-smokers for both males and 
females (Perez-Warnisher et al., 2018). In the region of the Western Pacific region, the 
daily smoking rate of males is fifteen times higher than in females, which is the largest 
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gender difference compared to the other places (Figure 1). However, as more and more 
women smoke, the difference in gender among these smokers will become smaller and 
smaller (Perez-Warnisher et al., 2019).  
Cigarette smoking is so prevalent that it has created a heavy economic burden on society. 
The cost of medical care associated with smoking in the United States alone is as high as 
$170 billion. The early death and productivity decline caused by smoking directly led to 
a loss of $156 billion (Do and Maes, 2016, Galanti, 2008). In addition, the economic 
burden of smoking has already reached 130 billion euros in Europe since 2000 (Galanti, 
2008), within which the cost has been estimated to range from £2.7 billion to £5.2 billion 
in the UK (Ekpu and Brown, 2015). 
 
 
 
Figure 1. The prevalence of smoking is largely related to gender and geography. 
Smoking distribution worldwide: A. Men smoking distribution. B. Women smoking 
distribution. The countries with the highest male smoking rates are mainly middle-income 
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countries, while the countries with the highest female smoking rates are mainly high-
income countries [quoted from (Perez-Warnisher et al., 2019)].  
 
1.2. Constituents of combustible tobacco products 
Combustion is a critical procedure in producing the reactive oxygen species (ROS). As 
combustion products, cigarette smoke has at least 6,500 chemicals in its solid and gaseous 
phases including more than 70 known carcinogens that are created by burning at least 600 
components in raw cigarettes (Stämpfli and Anderson, 2009, Talhout et al., 2011, Smith 
and Hansch, 2000, Hatsukami et al., 2008). The products after burning tobacco can be 
divided into gas and solid microparticles (Figure. 2) (Lee et al., 2012). The toxic 
components of cigarette smoke are mainly found in solid micro-particles (Witschi, 2004, 
Lee et al., 2012), containing toxins (e.g.; acetone, carbon monoxide, ammonia, nicotine, 
hydroquinone, etc.); carcinogens (e.g.; methylcholanthrene, benzo-α-pyrenes, etc.); and 
ROS (e.g.; nitrogen oxides, superoxide etc.) (Stämpfli and Anderson, 2009). Solid 
microparticles in the smoke can directly activate macrophages and epithelial cells in the 
lungs and jeopardize proteins, lipids, DNA, intracellular matrices and organelles, thus 
producing pro-coagulant and pro-inflammatory effects (Valavanidis et al., 2009). 
However, cigarettes could also possess immunosuppressive and anti-inflammatory 
features that can alter the transcription process (Modestou et al., 2010). What’s more, this 
condensate itself could indirectly produce secondary oxidation partitions and DNA 
adducts by inducing nitric oxide synthase and oxidative bursts within the body (Rahman 
et al., 2002). When smoke enters the body, it will cause oxidation, nitrosylation, 
acetylation and hydroxylation of the extracellular matrix, as well as interference with 
signal transduction, which will have a negative impact on cell activation and 
differentiation (Stämpfli and Anderson, 2009, Fowles and Dybing, 2003). 
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Figure 2. After burning, thousands of chemicals are produced from a cigarette. 
Nicotine, nitrosamines, polycyclic aromatic hydrocarbons and phenols are submicron 
solid particles, while other ingredients, such as carbon monoxide, nitrogen oxides and 
hydrogen cyanide, are gases (Perez-Warnisher et al., 2019). Moreover, most of these 
chemicals are toxic, while some damage the immune system, some cause cancer, and 
some are addictive (Lee et al., 2012) 
 
1.3. Smoking-related diseases 
1.3.1. Smoking and COPD 
Currently, the three main non-infectious causes of preventable death are COPD, 
cardiovascular disease, and lung cancer, all of which could be caused by smoking (Office 
of the Surgeon et al., 2004). Because of its high morbidity and mortality, COPD is a major 
public health issue that remains a challenge for clinicians in the 21st century (Fletcher 
and Peto, 1977). Exposure to cigarette smoke is a major risk factor for COPD, whether it 
is active or passive smoking, as passive or active exposure to CS leads to rapid dissolution 
and systemic uptake of toxins in the fluid of the oral/airway epithelial lining (Lee et al., 
2012). Besides, contact with indoor and outdoor air pollution and industrial dust and 
chemicals are other risk factors (Scanlon et al., 2000). Epidemiology has indicated that 
smokers with lung cancer or COPD are easy to combine with other diseases, which 
suggests that they have the same munity determinants (including oxidative stress and 
disorders of the inflammatory response) (Alberg et al., 2005). It is logical to conclude 
that the immunological mechanisms related to COPD as discussed above (munity 
determinants) are more or less the cancer determinants. As exhaustion of associated B 
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cells and alveolar macrophages, inflammatory responses are an important shared 
determinant for the development of lung tumors. On balance, COPD is the fifth leading 
cause of years of loss due to early death or disability globally and the third leading cause 
of death just after heart disease and cancer (Mathers and Loncar, 2006, Association, 2013).  
1.3.2. Smoking and cardiovascular disease 
Smoking also has a significant impact on the morbidity and mortality of cardiovascular 
disease. According to epidemiological studies, smoking increases the incidence of fatal 
coronary artery disease and myocardial infarction, regardless of gender (Health and 
Services, 2004, Jha et al., 2006, Health and Services, 2014). A total of 20% of all deaths 
from ischemic heart disease and 33% of all cardiovascular deaths globally are caused by 
smoking (Perez-Warnisher et al., 2019). There are also causal relationships and possible 
synergistic interactions between smoking and other major risk factors for coronary heart 
disease, such as hypertension, hyperlipidemia, and hyperglycemia (Benowitz, 2003, 
Perez-Warnisher et al., 2019). It is worth noting that non-smokers exposed to passive 
smoking at home or at work are also 25-30% more likely to have heart disease (Peters et 
al., 2013, Rea et al., 2002, Huxley and Woodward, 2011).  
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Figure 3 Smoking-related problems 
Cigarette smoke has a negative impact on all aspects of human health. Cardiovascular 
disease, respiratory diseases, and cancer are the three leading causes of smoking-
associated deaths. There are also other smoking-related health risks such as diabetes, 
weakened immune resistance, decreased fertility in males and females, wound healing 
disorders, and sexually transmitted diseases (Stämpfli and Anderson, 2009). 
1.3.3. Smoking and asthma 
The double function of smoking as an irritant and inhibitor is obviously performed in 
asthma. Atopy which is one of the important nonspecific risk factors for allergy can be 
suppressed by smoking, whereas the serum level of IgE is contradictorily raised by 
smoking. Smoking could significantly deteriorate the severity of the consequences of 
asthma via decreasing the sensitivity to corticosteroids (Chaudhuri et al., 2003),  
reducing lung function and directly damaging to the immune system. However, some 
inflammatory mediators are reduced in smokers with asthma, compared to non-smokers 
with asthma. In one study (Chalmers et al., 2001), the number eosinophilia in the sputum 
from asthmatic non-smokers, which is similar to the eosinophilia induced by antigens in 
the airway (Thatcher et al., 2008), was higher than in the sputum from asthmatic smokers 
(Robbins et al., 2005). As noted above, the deteriorating clinical manifestations of 
asthmatic smokers including impaired ability to clear pathogens and decreased steroid 
sensitivity, are closely related to smoking-induced macrophage dysfunction (Hodge et al., 
2007). In addition, asthmatic smokers may have irreversible airflow restrictions similar 
to COPD, and the asthma symptoms can be exacerbated by the increased risk of infection 
in smokers. Of particular note, epidemiology suggests that smoking in the womb and 
perinatal period could increase the risk of asthma in newborns (Bouzigon et al., 2008). 
1.3.4. Smoking and cancer 
Lung cancer is a well-known negative result of cigarette smoking, which is mutagenic. 
About 85% of patients with lung cancer are associated with smoking (Walser et al., 2008). 
Although lung cancer has been previously thought to have occurred mainly in men, the 
incidence of women’s lung cancer has increased by 6 times since the 1950s (Egleston et 
al., 2009). After the late 1980s, the incidence of women’s lung cancer in has surpassed 
that of breast cancer, ranking first in cancer deaths among women (Patel, 2005, General, 
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2001). People who start smoking at a young age are at greater risk of developing lung 
cancer, which is also closely related to cumulative lifetime smoking exposure (Health and 
Services, 2014, Jamal et al., 2015, Stanley, 1986). Furthermore, the carcinogenic impact 
of smoking is not confined to the lungs. Smoking could produce circulating carcinogens 
in the body that increase the incidence of other malignancies. Tobacco is connected with 
13 different kinds of other cancers such as liver, colorectal, pancreas and breast (Patel 
and Steinberg, 2016, Control and Prevention, 1993, Freedman et al., 2011). Worryingly, 
epidemiology suggests that exposure to cigarette smoke ingredient in the womb or 
perinatal period could increase the lifetime risk of tumors (Ng et al., 2006). Smoking may 
also reduce the activity of cytotoxic T cells which may take part in the process of tumor 
metastasis and recurrence after treatment (Ng et al., 2006).   
Some tumor formation processes, such as increased lymphogenesis and angiogenesis, 
weakened ability of macrophages to eliminate dying or transformed cells efficiently, 
release of the regional growth factor and its own receptor abduction, and increased gene 
mutation (including translocations, truncations and deletions), could be promoted by 
related inflammation (Stämpfli and Anderson, 2009). Evidence also suggests that 
bacterial inflammatory burden is increased in the lung, while in the meantime, lung 
intraepithelial neoplasia develops (Ji et al., 2006). These observations may provide a link 
between host defense defects, increased inflammation, and increased cancer risk. The 
promotion of inflammation and deficiency of host immune defense could contribute to 
the high morbidity of tumors. For example, the pro-inflammatory nuclear factor κB (NF-
κB) facilitates the growth and survival of tumors (Stämpfli and Anderson, 2009). In 
addition, matrix metalloproteinase 9 (MMP9) secreted by macrophages, mast cells or 
neutrophils could decompose the extracellular matrix, which has a closely relationship 
with tumor invasion and metastasis (Alberg et al., 2005). It has been emphasized that the 
airway epithelial cells bridge the development of COPD and the tumor formation and 
play a key role between them. Cancerous mutated epithelial cells have enhanced pro-
inflammatory responses, while they have a decreased ability to resist pathogens 
(Anderson and Bozinovski, 2003).  
Even though many lung cancer patients have undergone tumor resection at an early stage, 
their chances of developing tumor metastasis still remain very high, because primary 
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malignant tumors often release tumor cells that enter the blood circulation with the help 
of a disordered inflammatory reaction, resulting in metastasis (Nagrath et al., 2007, 
Maheswaran et al., 2008). Smoking can significantly raise the incidence of metastatic 
lung cancer, which is linked to impaired immune surveillance resulting from chronical 
cigarette exposure and repeated microbial infection (Lu et al., 2007). 
In addition, new research indicates that tobacco is responsible for age-related macular 
degeneration, adult onset diabetes, impaired immune system and increased susceptibility 
to tracheobronchial infections (Health and Services, 2014). Smoking can increase the 
mortality rate of colorectal cancer in women (Kenfield et al., 2008). New evidence 
suggests that ectopic pregnancy are associated with smoking (Jha et al., 2013, Patel and 
Steinberg, 2016). 
 
1.4 Smoking and fracture and wound healing  
1.4.1 Smoking and fracture healing  
Smoking causes delayed fracture healing not only by directly affecting osteogenesis but 
also by indirectly inducing smoking-related diseases that worsen the bone growth 
environment (Sloan et al., 2010). The more effective the treatment of smoking-related 
diseases, the better the musculoskeletal effect (Capewell et al., 2009). Among patients 
with spinal fusion or facet joint fusion, smoking has adverse effects on fracture healing, 
and the incidence of pseudoarthritis in smokers (40%) is usually higher than in non-
smokers (8%) (Brown et al., 1986). Non-smokers undergoing lumbar fusion surgery are 
more likely than smokers to successfully have vertebral fusion and return to work on time 
(Carpenter et al., 1996). There are several explanations for how smoking affects fracture 
healing, such as reduced blood supply to damaged sites, nicotine- induced attenuation of 
endothelial nitric oxide synthase function, low levels of antioxidants and vitamins, and 
high circulating ROS levels (Sloan et al., 2010). Other studies have shown that nicotine 
is toxic to calcitonin and osteoblasts (Gaston and Simpson, 2007). Cigarette smoke can 
affect bone health and accelerate femoral osteonecrosis and osteoporosis in males and 
females (Wright, 2006). Nevertheless, it was found that smoking women entered 
menopause two years earlier than female non-smokers and had a higher risk of 
osteoporosis (Baron, 1984). Because of increased accident rates, more work-related 
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damages, more car crashes, and increased bone vulnerability, smokers’ fracture rates are 
generally higher (Wen et al., 2005).  
1.4.2 Smoking and wound healing 
Skin, the first line of defense for innate immunity, is a physical and chemical fence. 
Therefore, skin damage causes pathological microorganisms to enter into the body and 
leads to disorders of homeostasis (Takada et al., 2017). Although skin wounds usually 
heal very quickly, delayed wound healing often occurs in smokers, elderly people, 
infected patients, immunocompromised patients, and diabetic patients (Takada et al., 
2017). Nicotine and related chemicals in tobacco could debilitate the regeneration of 
wound healing and soft tissue after fracture damage, thereby prolonging the healing time 
and reducing the quality of postoperative consequences (Pitts et al., 1999). Fibroblasts, 
acute phase proteins, growth factors and mesenchymal stem cells (MSCs) are key 
moderators of wound healing and are in contact with circulating substance that exists in 
the bloodstream linked to smoking (Czernin and Waldherr, 2003). This adverse reaction 
is common in the skin of chronic smokers who suffer from loss of skin elasticity due to 
abnormal function of fibroblasts (Frances et al., 1991). Smoking cessation can not only 
improve their lung and cardiovascular function, but also optimize the healing process 
after surgery (Frances et al., 1991). MSCs and Fibroblasts are important generators of 
cytokines that help induce an initial inflammatory response and play an key role in the 
granulation tissue formation (Sorensen et al., 2002). For example, chemokines that are 
essential for attracting neutrophils and other white blood cells to the wound site are 
released by fibroblasts and MSCs (Wong and Martins-Green, 2004). The fibroblasts may 
also be differentiated into myofibroblasts that play a key role in wound closure and 
contraction. Furthermore, fibroblast-like progenitor cells separated from hematoma of the 
fracture can evolve into chondrocytes, osteoblasts and adipocytes in vitro (Oe et al., 2007). 
Smoking is supposed to affect and worsen the above-mentioned pathophysiological 
processes (Wong and Martins-Green, 2004, Gabbiani, 2003). 
1.4.3 IL-4 and wound healing 
The immune response to tissue damage plays an important role in the healing process of 
the skin, which determines the rate and outcome of healing (Julier et al., 2017). 
Furthermore, the role of cytokines in the wound healing is getting more and more 
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attention. However, the function of IL-4 within skin coalescence was reported 
contradictorily. For example, it was reported by Yang et al. that keratinocyte proliferation 
was promoted by IL-4 and was suppressed by anti-IL-4 antibodies in proportion to the 
dose. IL-4 stimulated the keratinocyte cycle to S phase from GO/G1 phase. The 
expression of c-myc which plays a very important role in the keratinocyte proliferation 
was induced by IL-4 (Yang et al., 1996). Junghans et al. reported that IL-4 enhances 
proliferation of keratinocytes and the expression of B7/BBl (Junghans et al., 1996). IL-4 
treated keratinocytes demonstrated elevated ability to promote the proliferation of T-cells 
in the context of staphylococcal enterotoxin B (SEB). In addition, IL-4 was also reported 
to accelerate the healing of skin wounds in the mice and antagonists of IL-4 could delay 
the wound healing (Salmon-Ehr et al., 2000). Research completed by Elbe-BuÈrger et al. 
supported that IL-4 not only instigates the keratinocyte to propagate and motivates mast 
cells to reproduce, but also leads to deposition of collagen beneath the epidermal layer 
(Elbe-BuÈrger et al., 2002). However, other research showed that IL-4 resulted in the 
reduction of fibronectin leading to impaired keratinocyte wounding healing, which could 
be treated by local therapy with fibronectin (Serezani et al., 2017). This conclusion of IL-
4 inhibiting the fibronectin was also endorsed by the viewpoint of IL-4 polarizing 
macrophages suppressing the fibrosis (Eming et al., 2017). Moreover, involucrin 
expression was reduced both in the skin of IL-4 transgenic mice in vivo and in HaCaT 
cells treated with IL-4 in vitro (Bao et al., 2016). The existence of IL-4 could also disturb 
the integrity of cell sheets by causing the keratinocyte HaCaT cells to express decreased 
levels of DSG1and DSC1, which encode the desmosomal cadherins in the keratinocytes 
(Omori-Miyake et al., 2014, Tsuchisaka et al., 2014).   
 
1.5. Smoking and microbial infection  
Smoking is one of the main causes of systemic infections, especially respiratory 
infections, whether active or passive smoking (Arcavi and Benowitz, 2004). The 
incidence of diseases such as community acquired pneumonia (CAP), tuberculosis, 
invasive pneumococcal disease, postoperative mediastinal influenza, meningococcal 
disease (Coen et al., 2006, Murray et al., 2012), periodontitis, and surgical wound 
infections is increased in smokers (Steingrimsson et al., 2008, Cayci et al., 2008, Bates 
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et al., 2007, Bergstrom, 2004, Nuorti et al., 2000). The attributable risk ratios of smoking 
for the mortality of both pneumonia and influenza were 2.0 higher in males and 2.2 in 
females (Huttunen et al., 2011). A total of 6% of deaths from influenza and pneumonia 
are caused by smoking, which is more than deaths from other diseases caused by smoking, 
such as digestive system neoplasms (Correa et al., 2009, Huttunen et al., 2011). Studies 
have shown that smoke has a destructive effect on respiratory epithelial cells and mucosal 
immune systems. Smoke can promote the adhesion of bacteria on the surface of airway 
epithelial cells, impair the function of monocytes and macrophages, inhibit the production 
of immunoglobulins, destroy the ciliary activity of upper respiratory epithelial cells, and 
thus increase respiratory infections(Seaton et al., 2000, Dye and Adler, 1994). Parents 
smoking or other family members smoking can cause bronchitis, bronchiolitis or lower 
respiratory tract infection in newborns(Jones et al., 2011). Active and passive smoking is 
linked to primary tuberculosis, active tuberculosis, and risk of recurrent tuberculosis, 
while over 20% of global tuberculosis mortality is due to tobacco (Perez-Warnisher et al., 
2019, Organization, 2007).  
Smoking could aggravate the intensity of the pro-inflammatory response to pathogens 
without the reduction of pathogens-specific memory or pathogens clearance (Gualano et 
al., 2008). Therefore, the elementary immune protection has been compromised by 
smoking. However, the secondary inflammatory processes have remained unaffected 
(Robbins et al., 2006). Smoking could augment the numbers of goblet cells, decrease 
mucosal ciliary mobility and induce the hypersecretion, which reduces the removal of 
pathogens and increases their colonization (Patel et al., 2002). The high level of 
inflammatory response is linked to the raised yield of pro-inflammatory mediators 
resulting from smoking (Stämpfli and Anderson, 2009). In addition, a study suggested 
that the intense inflammation resulted in stepped-up airway fibrosis and emphysema, 
giving evidence that the pathogenesis of emphysema could be on account of the changed 
response to pathogens (Kang et al., 2008). Likewise, inflammation response was found 
to be aggravated in smokers with the presence of Haemophilus influenza and 
Pseudomonas aeruginosa, which are linked to the deterioration of COPD (Gaschler et al., 
2009).   
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1.6. Four types of bacteria 
1.6.1 Staphylococcus aureus 
Staphylococcus aureus (S. a.) is a Gram-positive round bacterium that is commonly found 
in the upper respiratory tract and skin (Masalha et al., 2001). S. a. can be of a “parasitic” 
nature, living in 30% of the normal population without being harmful to the host 
(Akmatov et al., 2014, Rao et al., 2015). As a main cause of community-associated and 
hospital-associated microbial infection (David and Daum, 2010), S. a. is often associated 
with severe pneumonia, suppurative osteomyelitis, infective endocarditis, bacteremia and 
sepsis. Methicillin-resistant Staphylococcus aureus (MRSA) and its resistance to multiple 
drugs is increasing, making infection control very tricky (Junie et al., 2014). Hospital-
associated-MRSA often infects individuals who have associated risk factors such as being 
in a post-operation, ventilator use, and prolonged hospitalization. However, those who do 
not have these risks are often infected with methicillin sensitive Staphylococcus aureus 
(MSSA) or community-associated-MRSA (Tokajian, 2014). 
1.6.2. Staphylococcus epidermidis 
Staphylococcus epidermidis (S. e.) is a Gram-positive and facultative anaerobic bacterium. 
It is also a part of the normal flora in human beings and is usually found on the skin (Fey 
and Olson, 2010). Although S. e. does not have pathogenicity under normal conditions, 
once the body's immunity declines, it is likely to cause infection. This infection usually 
occurs during hospitalization, especially happening to postoperative patients with 
implants such as catheters, tracheal tubes and chest tubes (Levinson, 2008, Natsis and 
Cohen, 2018). Actually, S. e. is now considered to be the most common cause of hospital 
sepsis (Nguyen et al., 2017). S. e. can form biofilms that grow on those devices, which 
makes it very difficult for antibacterial drugs to be effect (Wilson et al., 2011, Xie et al., 
2019). This biofilm prevents immune responses by creating a physical barrier while 
producing anti-inflammatory effects to a certain extent (Spiliopoulou et al., 2012). S. e. 
has also been reported as a pathogenic bacteria for skin and soft tissue infections 
(Akiyama et al., 1998, Mustafa et al., 2016). 
1.6.3. Pseudomonas aeruginosa 
Pseudomonas aeruginosa (P. a.) is a Gram-negative common rod-shaped bacterium with 
an encapsulated structure. It is an opportunistic pathogen that can bring about fatal 
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hospital-acquired infections, such as septic syndromes, ventilator-associated pneumonia 
and wound non-healing, when the immunity of humans is impaired (Ciszek-Lenda et al., 
2019, Lore et al., 2012, Watters et al., 2013). Interestingly, P. a. could increase the 
infection burden in smokers. However, when stimulated by Haemophilus influenza, the 
infection burden associated with exposure to P. a. is great (Drannik et al., 2004). P. a. 
which is the most common cause of chronic pneumonia is also the leading cause of the 
hereditary cystic fibrosis (Waters and Goldberg, 2019, Cigana et al., 2009). P. a. is also 
capable of forming biofilms; as a consequence, it is highly pathogenic and resistant to 
multiple antibiotic treatments (Alhede et al., 2014). Bacterial infections with biofilms are 
often dominated by chronic inflammation. Although the body has a large amount of 
neutrophil infiltration, these neutrophils destroy the body's immune system rather than 
the bacteria itself (Roilides et al., 2015, Marcinkiewicz et al., 2013). There are two 
explanations for the pathogenicity of bacterial biofilms: one is that the bacteria hide in 
the biofilm’s matrix, avoiding contact with immune cells and antibodies; another is that 
the bactericidal effect of macrophages entering the biofilm’s matrix is weakened 
(Hirschfeld, 2014). 
1.6.4. Enterococcus faecalis  
Enterococcus faecalis (E. f.), is a Gram-positive opportunistic pathogen that has come to 
existence as a leading cause of hospital-associated infections globally (Lossouarn et al., 
2019, Lebreton et al., 2014). Normally, it belongs to the normal flora of the 
gastrointestinal tract as early as infancy (Gilmore et al., 2014) but can cause hospital-
acquired pneumonia, gastrointestinal infections, urinary tract infections (30%), 
reproductive system infections, endocarditis, peritonitis (Agudelo Higuita and Huycke, 
2014), bacteraemia (10%) and wound non-healing (70%) when the body's immunity is 
weakened (Tien et al., 2017, Wisplinghoff et al., 2004, Maki and Tambyah, 2001, Hidron 
et al., 2008, Gjødsbøl et al., 2006). Biofilm formation, avoidance of immune cell attack, 
and long-term survival in neutrophils and macrophages, allow E. f. to successfully 
colonize in the host (Baldassarri et al., 2005, Zou and Shankar, 2016, Zou and Shankar, 
2014). E. f. can be found in 30%-90% of re-infected root canal treated teeth (Molander et 
al., 1998). Plasmid-encoded haemolysin of E. f., known as cytolysin, is critical for the 
invasion pathogenesis in animal models, and its concomitant existence with high levels 
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of gentamicin resistance could increase the risk of death in patients with bacteremia by 
five times (Chow et al., 1993). Moreover, plasmid-encoded adhesion, known as 
aggregating substance, could augment its virulence in the infectious process (Hirt et al., 
2002). 
 
1.7. Smoking induces inflammation while suppressing immune function at the 
same time 
Toxic substances in smoke and oxidative activators produced by combustion cannot be 
filtered out by cigarette holders (Huang MF, 2005). The particulate and gaseous 
components of cigarette smoking first interact with the immune system of the oral, nasal 
and tracheal mucosal surfaces (Lee et al., 2012) (Figure 4). Furthermore, the semiquinone 
radicals that exists in the particulate phase could continuously produce the ROS. Then, 
ROS induces DNA damage by sensitizing the oxidative cellular pathways and triggering 
peroxidation of lipids or other components of the airway epithelial cell membrane 
(Valavanidis et al., 2009, Kim et al., 2004). The ROS also induces the activation of 
inflammatory genes, by initiating the signaling cascades (Chung, 2005, Churg et al., 
2002). The production of these inflammatory mediators can gear up the recruitment of 
chronic immune cells. The effects of smoking on the body's inflammatory system are not 
only stimulatory, but also inhibitory. The subsequent adaptive T lymphocytes can be 
classified as three T helper cells: Th1, Th2 and Th17, which have different priorities to 
activate the transcriptional factors to express special cytokines (Zhou et al., 2009). For 
instance, Th1 cells produce IFN-γ, which is a pro-inflammatory cytokine, whereas Th2 
cells produce IL-4, which is an anti-inflammatory cytokine (Zhou et al., 2009). Smoking 
could weaken the function of Th1 cells while facilitating the response ability of Th2 cells, 
thus suppressing the development of Th1 inflammation and enhancing the Th2 responses 
(Nakamura et al., 2008). When stimulated by bacterial lipopolysaccharide (LPS), the 
reactive ability of dendritic cells that exposed to smoking was reduced, and was 
accompanied by the decreased secretion of IL-12 (Th1 cytokine) and IL-23 (Th17 
cytokine) (Vassallo et al., 2005). Smoking could enhance the Th2 immune responses, 
such as eosinophilic recruitment in the airways (Phaybouth et al., 2006). Although there 
is no definitive evidence that smoking promotes the Th17 polarization immune response, 
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it has been reported that long-term chronic exposure to smoke can contribute to Th17 
involvement in autoimmune responses (Shan et al., 2009, Heliövaara et al., 1993). 
Smoking can aggravate the extent of influenza virus and bacterial infection, and could 
also increase the prevalence of tuberculosis (Kolappan and Gopi, 2002, Nuorti et al., 2000, 
Kark et al., 1982). The underlying mechanisms include the regulation of signal 
transduction of airway epithelial cells and immune cells and suppression of congenital 
and adaptive immune responses (Gualano et al., 2008). 
 
Figure 4. Sketch of respiratory immune defense, immune stabilization and immune 
surveillance impaired by smoking [modified according to (Stämpfli and Anderson, 2009)].  
Smoking attracts inflammatory cells to the lung parenchyma from the microcirculation, 
which sequentially affects epithelial cells and macrophages. While smoking promotes 
inflammation, congenital defenses, including NK cells, macrophages, dendritic cells, 
epithelial cells, are also damaged, which increases the risk, severity and duration of 
infection. Impaired immune stabilization was demonstrated in the following aspects: 
reduced ability to clear dead cells, increased abduction of IL-17-producing effector T 
cells and remains of amplified CD8+ T cells, increased autoantibodies and related 
autoimmune loops produced by lymphoid gathering B cells and T cells together. Smoking 
induces tumor-associated macrophages to produce more inflammatory proteases, which 
facilitate the tumor metastasis by degenerating the extracellular matrix, destroying the 
tight link between the cells. Therefore, immune surveillance has been compromised 
(Stämpfli and Anderson, 2009).  
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Smoking modulates the development of a Th2 allergy status by activating sensitizing 
factors. Smoking causes airway smooth muscle cells and epithelial cells to produce 
Thymic Stromal Lymphopoietin (TSLP), which induces dendritic cells to increase the 
Th2 polarization (Smelter et al., 2010). Investigation of single nucleotide polymorphisms 
in the TSLP gene uncovered the gene variants that were more vulnerable to inducement 
as a result of elevated attraction for AP-1 transcription factor binding (Harada et al., 2009). 
In addition, some TSLP gene polymorphisms would cause bronchial epithelial cells to 
produce more TSLP when influenza virus infections were present. TSLP activation is 
important mechanism for smoking to increase a permissive effect on hypersensitive 
inflammation in the respiratory tract. Smoking could decrease the production of IL-12 
and IL23, while increasing the secretion of IL-8 and IL-10, in dendritic cells stimulated 
by CD40 ligand or LPS (Kroening et al., 2008). It has been shown that the ability of 
dendritic cells that were incubated with smoking to stimulate T cells was reduced (Mortaz 
et al., 2009). These consequences, intermediated by diversified inflammatory signaling 
factors, are induced by various smoking components, such as nicotine, ROS and other 
chemicals (Vassallo et al., 2008). It indicates that exposure to smoking in mice reduces 
the activation of dendritic cells in the lung, which decreases their ability to activate 
antigen-specific T cells propagation and to promote Th1 polarizing (Robbins et al., 2008). 
However, the ability of dendritic cells to move to the lymph nodes remains and is possibly 
even augmented (Robays et al., 2009). Except for dendritic cells, both B cells and 
macrophages have antigen presenting cell functions (Lee et al., 2012). The function of 
macrophages, which are increased and present in the sinuses and respiratory tract of 
smokers notwithstanding, is damaged by ROS in smoking (Kirkham et al., 2004). 
Smoking can reduce the ability of phagocytic cells to phagocytose bacteria and apoptotic 
cells, leading to the accumulation of debris of inflammatory cells and apoptotic cells and 
ultimately delayed wound healing (Kirkham et al., 2004). It is not clear whether smoking 
has an effect on the production of TNF-α in macrophages (Yang et al., 2006). For instance, 
one study (Pessina et al., 1993) reported that exposure to smoking could stimulate the 
macrophages to produce more TNF-α, whereas another study showed that the 
macrophages secreted less TNF-α when exposed to smoking (Gaschler et al., 2008). 
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Evidence (Mian et al., 2008) has revealed that NK cells secreted less TNF-α and IFN-γ 
and showed weaker cytotoxic effects in smokers than in nonsmokers. 
 
1.8. Smoking related inflammatory cells  
1.8.1. Airway epithelial cells 
The respiratory ciliated columnar epithelium is the first line of defense against bacterial 
viruses. The overlying mucous gel layer can cleanse, phagocytose and kill pathogens, and 
the barrier function is obtained via tight junctions. However, smoking directly impairs 
the completeness of this barrier by increasing the permeability of the airway epithelial 
cells and compromising the clearing ability of mucus(Dye and Adler, 1994, Burns et al., 
1989). Although smoking can stimulate the respiratory epithelium to produce pro-
inflammatory factors, when there is a bacterial or viral infection, the pathogen-associated 
molecular patterns (PAMPs) (Pace et al., 2008) were attenuated, including LPS and 
pathogen double-stranded RNA which binds to TLR (Toll-like receptor) (Bauer et al., 
2008). It has been confirmed that the epithelium can secrete significantly more 
inflammatory factors when incubated with pathogen double-stranded RNA and cigarette 
smoke extract (CSE). Although the inflammatory level is raised by the stimulus of CSE, 
the ability of this inflammatory status to kill the bacteria or viruses is decreased. One 
possible explanation is that smoking reduces the production of β-defensin-2 (van der 
Toorn et al., 2007). Besides, the β-defensin-2 was significantly decreased in the sputum 
and pharyngeal fluid of smokers with acute pneumonia, compared to nonsmokers acute 
pneumonia (Herr et al., 2009).    
1.8.2. Alveolar macrophages 
Smoking could augment the quantity of macrophages in pulmonary alveoli (Sopori, 2002) 
and stimulates them to generate more ROS, proteolytic enzymes, and pro-inflammatory 
mediators, further explaining the relationship between smoking and tissue damage and 
inflammation at the cellular level (Sopori, 2002, Russell et al., 2002). Like airway 
epithelial cells, the ability of macrophages to swallow bacteria and dead cells is reduced 
by smoking, and so is the ability to respond to PAMPs (Chen et al., 2007, Drannik et al., 
2004, Gaschler et al., 2008). As a consequence, those necrotic or apoptotic cells that are 
not cleared can secrete related secondarily inflammatory chemicals, such as ligands of 
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the receptor for advanced glycation end-products (RAGE) and high-mobility group box 
1 protein (HmGB1) (Liu et al., 2008). At the same time, related anti-inflammatory 
activities fail to function properly in this process, which is modified by TNF. From a 
mechanism perspective, it is imaginable that the production of a pro-inflammatory factors 
responsive to TLR activation is decreased due to the upregulated threshold that is changed 
by continuous stimulation of smoking. There is evidence that the smoking-associated 
pulmonary inflammation is prompted by the TLR4 agonist heat-shock protein (70HSP70), 
which induces the primary response gene 88 (MyD88) related signal route. It was reported 
that smoking could also trigger alveolar macrophages to display different inflammatory 
features with the stimulation of microbial infection, such as Haemophilus influenza 
(Gaschler et al., 2009). Furthermore, with the presence of Haemophilus influenza, the 
smoking alveolar macrophages could produce significantly more CC-chemokine ligands, 
such as CCL2, CCL9 and CCL10, which are pro-inflammatory mediators, while secreting 
less TNF. The nature of this change may be one of the determining factors in the 
susceptibility to disease. There is an evidence that the alveolar macrophages in smokers 
have different conditions of activation, compared to the alveolar macrophages in non-
smokers (Woodruff et al., 2005). Smoking may cause some M1-type macrophages to be 
inactivated, while some M2-type macrophages are activated (Woodruff et al., 2005). This 
role of smoking in the differentiation of macrophages has important significance for the 
development of the disease, as M1 alveolar macrophages are related to significant lung 
injury, such as emphysema, while M2 alveolar macrophages are associated with tumor 
development (Stämpfli and Anderson, 2009). The molecular mechanisms by which 
alveolar macrophage reactivity changes are not yet clear, but they can be repaired by 
exposure to the reduced state of glutathione, which means that the process involves 
oxidative stress (Woodruff et al., 2005). From subclinical inflammation to the outcome 
as cancer and COPD, in addition to the differential activation of alveolar macrophages, it 
is also related to the susceptibility of the body (Stämpfli and Anderson, 2009). The 
underlying mechanisms are not fully understood, but some host factors are suggested to 
increase the risk of developing related diseases. Host factors that include uncontrollable 
inflammatory responses, tendency to autoimmune diseases (Taraseviciene-Stewart et al., 
2005), allergic constitution (Postma and Boezen, 2004), damaged oxidative defense, 
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connective tissue and matrix repair related genes mutations (Just et al., 2005), diminished 
detoxification enzyme (such as epoxide hydrolase and cytochrome p450 isozymes), blind 
elimination of effector cells leading to secondary necrosis (Hodge et al., 2007), 
accelerated cellular aging process (Ito and Barnes, 2009), vascular repair defects (caused 
by decreased vascular endothelial growth factor) (Taraseviciene-Stewart et al., 2005), and 
mutated genes that control DNA damage response and DNA repair (Rangasamy et al., 
2004), could contribute to the increased risk of smoking related diseases, such as 
emphysema, lung cancer. The risk of infection is further complicated by defects or 
polymorphisms in the host’s congenital and acquired immune responses (Becker and 
O’Neill, 2007).  
1.8.3. Natural killer (NK) cells 
NK cells are important for the innate immune system both in fighting against microbial 
invasion and preventing tumors through releasing the granzymes, perforin and chemokine 
and pro-inflammatory cytokines (Swann et al., 2007). Some studies have suggested that 
smokers have a lower number and cytotoxic activity of NK cells than in nonsmokers, 
which associates NK cells dysfunction with infections and tumors (Tollerud et al., 1989, 
Mian et al., 2008, Lu et al., 2006). Studies have also shown that cancer metastasis is 
inseparable from the weakening of immune surveillance by NK cells(Ng and Travis, 
2008). Furthermore, the recurrence of pulmonary infection is also associated with 
functional defects in NK cells. 
1.8.4. Dendritic cells 
As important antigen presenting cells, Dendritic cells are essential to activation of 
immune reaction (Mellman and Steinman, 2001). Because they are directly in the alveolar 
space or under the lung epithelium, they are extremely susceptible to smoke (McComb et 
al., 2008). Dendritic cells play an important role in the modulation of the immune system, 
owing to their influence on both innate and adaptive immunity. Related research has 
shown that the chemokine CX3CL1, which is induced by dendritic cells, is increased in 
emphysema. Mature dendritic cells are decreased in the airways of smokers with COPD, 
and after smokers quit smoking, their mature dendritic cells returned to the level of non-
smokers (Jahnsen et al., 2006). By comparison, smokers with COPD had higher level of 
naïve dendritic cells than smokers without COPD or nonsmokers (McComb et al., 2008). 
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In other words, the maturity condition and the quantity of dendritic cells are highly 
sensitive to smoking, which causes an immune response disorder. The underlying 
mechanism may be that the Th17 cytokine IL-23 and Th1 cytokine IL-12 have been 
downregulated (Robbins et al., 2008).   
1.8.5. B cells 
Autoimmunity plays an important role during the process from smoking to lung disease, 
within which the B cells are substantially present. Smoking can stimulate the related 
tissue to generate significantly more granulocyte-macrophage colony-stimulating factor 
(GM-CSF), which secondarily induces the dendritic cells to present the antigens and 
promote Th2 immune responses (Trimble et al., 2009). There is an evidence that all the 
immunoglobulin serum levels, except IgE, can be reduced by smoking. It is reported that 
smoking weakens the ability of antibodies to neutralize the extraneous antigens, and 
smoking can induce lymphoid follicles in lungs to sensitize the B cells to induce allergic 
reaction and to increase their response to autoantigens, which damages the tissues 
(Trimble et al., 2009). Autoimmune attacks take part in the development of COPD or 
emphysema caused by smoking. Currently known autoantibodies in lungs involved in the 
process are elastin antibodies, epithelial cell antibodies and endothelial cell antibodies 
(Lee et al., 2007, Feghali-Bostwick et al., 2008). As many inflammatory circumstances 
contain autoantibodies, but without pathogenesis, their etiological role is debatable. 
1.8.6. T cells 
Notably, there are significantly more cytotoxicity T lymphocytes (CTL) in the lungs of 
smokers with COPD or emphysema, compared to nonsmokers or smokers without 
emphysema or COPD. Actually, the CD8+ T cells are increased through exposure to 
smoking and could remain for at least 6 months after stopping smoking (Motz et al., 2008). 
Accordingly, the T cells could promote alveolar macrophages to secrete more MMP, 
which is an important elastase that degrades fibrin or matrix, leading to emphysema 
(Grumelli et al., 2004). Moreover, CD8+ T cells could also meditate the inflammatory 
response and induce the destruction of tissue (Maeno et al., 2007). The defensive ability 
of CD8+ T cells is reduced by smoking, whereas the specific memory to fight against 
pathogens is preserved (Gualano et al., 2008). Smoking could reduce the TCR repertoire 
breadth in lungs and continuously increase the susceptibility to the pathogens. 
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Interestingly, smoking activates the Th17 cells, while suppressing the regulatory T cells 
during the development of smoking related diseases (Harrison et al., 2008, Barcelo et al., 
2008).      
 
1.9. Smoking related signal transduction pathways 
Several important singling pathways have been interrupted by smoking, such as NF-κB, 
mitogen-activated protein kinases (MAPK), activated protein 1 (AP-1), and Janus 
kinases/signal transducer and activator of transcription (JAK-STAT) (Kroening et al., 
2008). These pathways are involved in the inflammatory cells activation, regulation, and 
proliferation (Samet and Wipfli, 2010). Smoking influenced stimulation of the 
transcription factors of AP-1 and NF-κB is associated with changed responsiveness to 
acute invasion of pathogens, modulation of inflammatory chemokine production, 
changed adjustment of cell death, and changed resistance to corticosteroids (Modestou et 
al., 2010). It is also reported that NF-κB, a promoter for the expression of many 
inflammatory factor, which is essential for preventing cell death, can be activated by 
smoking, and the anti-apoptotic factors can be up-regulated by smoking (Liu et al., 2008). 
Smoking elevates the activity of Ras protein (cellular signal transduction) within the 
epithelial cells, which is reliant, at least in part, on the activation of the RAGE (Reynolds 
et al., 2011). It has been reported that increased Ras activity is a hallmark of lung cancer 
derived from epithelial cells and an important cellular juncture for the activation of RAGE 
induced by smoking, which can ultimately lead to NF-κB activation that is the 
downstream of RAGE (Bos, 1989). Furthermore, apart from directly activating NF-κB, 
smoking also cools down the high responses of NF-κB in the stressed epithelial cells 
stimulated by pathogens (Manzel et al., 2011). There is evidence that when stimulated by 
Haemophilus influenzae, smoking mice have inhibited NF-κB and decreased the 
expression of defensive inflammatory factors, whereas the nonsmoking mice have 
promoted NF-κB and produced more relative inflammatory factors (Manzel et al., 2011). 
Therefore, it could be concluded that smoking on one hand could activate NF-κB without 
infection, and on the other hand, it could also suppress NF-κB with the presence of 
infection. The AP-1 signaling pathway, important for the resistance to corticosteroids 
inflammation, also plays a pivotal role important in the production of IL-8 in 
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macrophages and monocytes, which are activated by ROS in smoking (Walters et al., 
2005). Smoking itself can induce AP-1 activation in bronchial epithelial cells 
independently, but in the case of pre-stimulation with LPS, the activation-effect of 
smoking on AP-1 is weakened (Laan et al., 2004). These studies give strong backing to 
the viewpoint that smoking downregulates the mucosal defensive function and induces 
chronic inflammation in the airways, giving rise to reduced acute reactivity to infectious 
attacks (Lee et al., 2012).  
      
1.10. Aim of the project 
Smoking causes many health problems, and smoking-induced infections are getting more 
and more attention. Since impaired immune function plays an important role in 
prerequisites for microbial infection, focus will be put on the effect of smoking on the 
immune function. S. a., S. e., P. a., E. f. are four types of pathogenic bacteria that are 
commonly seen in clinical infection. Human peripheral blood mononuclear cells (PBMCs) 
consist of lymphocytes (T cells, B cells and NK cells) that occupy the most part, 
monocytes that take up a small part, and only a small percentage of dendritic cells 
(Verhoeckx et al., 2015). The following questions are addressed of this thesis: 
1. How smoking affects the release of cytokines by PBMC?  
2. How does the production of pro-inflammatory and anti-inflammatory factors changes 
when PBMCs from smokers and non-smokers are exposed inactivated bacteria?  
3. Since some articles reported that IL-4 could facilitate the wound healing, whereas 
others showed that IL-4 inhibited the wound healing. Whether IL-4 promotes or inhibits 
wound healing? 
4. How smoking affects wound healing by IL-4?  
As for my own project, the hypothesis is that the levels of cytokines released by PBMCs 
must have been changed in smokers compared to nonsmokers. Based on this, different 
cytokine amounts released by the PBMCs of nonsmokers and smokers when stimulated 
by four types of inactivated bacteria (S. a., S. e., P. a., E. f.) will be investigated. In 
addition, the migration rate of HaCaT cells will be measured with or without the presence 
of IL-4. HaCaT cells are immortal human keratinocytes that have been widely used to 
simulate the pathophysiological activity of the skin in vitro (Seo et al., 2012). Meanwhile, 
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the migration rate of HaCaT cells treated by different IL-4 conditions that were produced 
by PBMCs when stimulated by the four types of inactivated bacteria will also be 
measured. The aim is to clarify the effects of smoking on cytokines and the effects of 
altered IL-4 induced by smoking on skin healing, thus providing a theoretical basis for 
the treatment of clinical smoking induced infections and delayed wound healing.  
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2. Materials and methods  
2.1. Materials 
2.1.1. Chemicals 
Table 1. List of solids, solutions and buffers used in the project  
Article Company Article number 
30% Hydrogen peroxide Solution Roth CP26.5 
Acetic acid Roth 3738.4 
BSA Roth 8076.4 
DMEM high glucose (4.5 g/l) with L-Glutamine Sigma D5796 
DPBS Sigma D8537 
DPBS Sigma H15-002 
Ethanol, 70% Apotheke     MRI 
Ethanol, 99% Apotheke     UKT 
FCS Invitrogen 41G7141K 
LSM 1077 PAA J15-004 
Penicillin/Streptomycin Sigma P0781 
Resazurin sodium salt Sigma 199303-1G 
RPMI 1640 Sigma R8758 
SRB salt Sigma S1402-1G 
TRIS Roth AE15.1 
Trypan Blue 0.5% 100 ml Biochrom L6323 
Trypsin/EDTA Sigma T3924 
Tween 20 Roth 9127.1 
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Table 2. Buffers, Solutions and Mediums 
Buffers/Solutions/Mediums Compounds 
ELISA Washing Buffer 0.05% Tween-20 in DPBS 
ELISA Blocking Buffer 1% BSA in DPBS 
Diluent 0.05% Tween-20 and 0.1% BSA in PBS 
ABTS reaction buffer 0.1 M citric acid solution 
ABTS stock solution 15 mg ABTS in 1 ml ddH2O 
ABTS reaction solution 5 ml ABTS reaction buffer 
+ 100 µl ABTS stock solution 
+ 5 µl 30% H2O2 
1% Acetic Acid Solution 1% acetic acid in ddH2O 
10 mM TRIS Solution 1.2 g TRIS in 1 L ddH2O 
SRB Solution 0.4% SRB in 1% acetic acid 
Resazurin stock solution 0.025% in DPBS 
Resazurin working solution 10% Resazurin stock solution in DPBS 
HaCaT Cells Culture Medium 500 ml DMEM 
5 ml Penicillin/Streptomycin 
25 ml Fetal Bovine Serum  
 
2.1.2. Equipment 
Table 3. List of used apparatus 
Equipment Manufacturer Type Serial number 
Agitator, magnetic stirrer IKA-Werke GmbH  RH B2 06.050357 
Agitator, magnetic stirrer Heidolph Instruments GmbH MR Hei-Mix L 040700340 
Blood Needle Multifly 0.8×19 mm 85.1638.235 
Blood Tube S-Monovette 9 ml 02.1726.001 
Cell culture plate Greiner bio-one 96-well, flat bottom 655180 
Cell culture plate Corning Inc. 48-well, flat bottom 3548 
Cell culture plate Greiner bio-one 24-well, flat bottom 662160 
Cell culture plate Corning Inc. 6-well, flat bottom 353046 
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Cell Star Tubes Greiner bio-one 50 ml 227261 
Cell Star Tubes Greiner bio-one 15 ml 188271 
Centrifuge Dako Deutschland GmbH Stat Spin 620E50000693 
Centrifuge Thermo Fisher Scientific Megafuge 40 R 41307652 
Centrifuge Scientific Industries Inc. SI DD 58 DD 58-1001 
Centrifuge（Mirco） Labnet International BN 08060235 C 1301 B 
Centrifuge（Mirco） HERAEUS Med GmbH Fresco 17 41250019 
ELISA plate Greiner bio-one 96-well, flat bottom 655061 
Encapsulator NISCO Engineering AG UNIT VAR V1 LiN-0172 
Eppendorf tube SARSTEDT AG 0.5 ml, white 72.699 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, white 4182.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, blue   4190.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, green 4209.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, red 4189.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, yellow  4204.1 
Eppendorf tube Eppendorf 2.0 ml, white 2549 
Freezer -20 ℃ BSH IQ500 GS51NYW41 (01) 
Freezer -20 ℃ Liebherr Med Line LGex3410-21K 001 
Freezer -80 ℃ Thermo Fisher Scientific 905 827860-2521 
Freezer -86 ℃ Revco ULT1386-9-V17 R10G-333095-RG 
Fridge +4 ℃ Liebherr Comfort 3523-21L 
Fridge +4 ℃ Cool Compact Kühlgeräte G HKMT 040-01 CC00412514 
Gauze Gazin 7.5×7.5 cm 2 stk/pcs 13621 
Ice maker Scotsmen AF 80 DD 8837 11 X 
Infusion syringe pump B. Braun  Perfusor Secura FT 2313 
Infusion syringe pump B.Braun Perfusor Space 137783 
Infusion syringe pump KD Scientific Inc. KDS-100-CE 114297 
Infusion syringe pump Landgraf Laborsysteme LEBC 280673 
Incubator  Thermo Fisher Scientific Heratherm OMS 60 41296334 
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Incubator Binder GmbH 9040-0078 11-22649 
Incubator Binder GmbH 9040-0081 11-22190 
Laboratory pump (Bench) Carl Roth GmbH + Co.KG Cyclo 2 1109-065 
Liquid pump (Bench) KNF Neuberger GmbH N86KN.18 2.04119556 
Microplate Reader BMG Labtech GmbH FLUOstar Omega  S/N415.1264 
Microscope Peqlab Biotechnologie GmbH EVOS-fl 91-AF-4301 
Mixer Corning Inc. Vortex Mixer 804995 
Mixer Labinco BV LD-76 76000 
Multichannel Pipettor Corning Inc. 5-50 µl 151620022 
Multichannel Pipettor Corning Inc. 20-200 µl 551630277 
Multichannel Pipettor Thermo Electron Co. 0.5-10 µl CH98998 4510 
Multichannel Pipettor Corning Inc. 50-300 µl 151640033 
pH meter Mettler-Toledo GmbH Five Easy FE 20 1232315296 
Pipette controller Integra GmbH Pipetboy acu 629619 
Pipette controller Heathrow Scientific LLC Rota-Filler 3000 HSA05119 
Pipette Tips Sorenson BioScience, Inc.  0.1 - 10 µl Colorless 
Pipette Tips Sarstedt AG & Co. 2 - 200 µl Yellow 
Pipette Tips Ratiolab GmbH 100 - 1000 µl Blue 
Refrigerator  Cool Compact Kühlgeräte G HKMT 040-01 CC 00412516 
Refrigerator  Cool Compact Kühlgeräte G HKMN 062-01 CC 00412513 
Safety workbench Thermo Fisher Scientific Maxisave S2020 1.8 41293949 
Safety workbench Thermo Fisher Scientific Maxisave S2020 1.8 41293948 
Scale Kern & Sohn GmbH ABJ 120-4 M WB 1140084 
Shaker, laboratory LTF Labortechnik GmbH DRS 12 11 DE 243 
Shaker, laboratory Peqlab Biotechnologie GmbH ES-20 010111-1107-0119 
Shaker, laboratory LTF Labortechnik GmbH DRS 12 11 DE 090 
Shaker, Laboratory  Corning Inc. LSE Vortex Mixer 1101260 
Single-channel Pipettor Corning Inc. 0.5-10 µl 158220060 
Single-channel Pipettor Corning Inc. 2-20 µl 158230441 
Materials and methods 
 32 
Single-channel Pipettor Corning Inc. 10-100 µl 158240031 
Single-channel Pipettor Corning Inc. 20-200 µl 158250088 
Single-channel Pipettor Corning Inc. 100-1000 µl 058261237 
Single-channel Pipettor Eppendorf  0.1-2.5 µl P35434B 
Spectrophotometer BMG Labtech GmbH Fluostar Omega 415-1264 
Water-bath Lauder Dr. R. Wobser GmbH Al 25 LCB 0727-11-0094 
Water-bath Lauder Dr. R. Wobser GmbH ECO ET 20 LY 06.1 
 
2.1.3. Software 
Table 4. List of used Software 
Software Company 
ImageJ  NIH  
Excel, Powerpoint, Word  Microsoft  
GraphPad Prism  GraphPad Software Inc.  
TScratch CSE-Lab 
EndNote X8 Thomson ResearchSoft 
 
2.2. Methods  
2.2.1. Ethics statement 
The study was performed according to the Declaration of Tübingen University and 
approved by the Regional Committee of Medical Research Ethics at Tübingen University 
(Ethical vote number, 538/2016BO2). Each donor was informed in advance of the 
purpose of the blood collection and the plan of our experiment, which obtained the 
agreement of all the participants. 
2.2.2. Blood collection 
The appropriate number and size of the test tubes were prepared for use. The donor was 
positioned in a chair, leaving the forearm horizontally placed on the table. When a vein 
was selected, the puncture point was cleansed in a circular motion from the inside out. 
After the puncture site was air-dried, it was not touched or palpated. If it was necessary 
to reassess the site by palpation, the area was re-cleaned prior to venipuncture. The donor 
was instructed to make a fist, making the veins slightly swell, and then the needle was 
Materials and methods 
 33 
quickly inserted through the skin into the venous lumen. The needle was inserted at an 
angle 15-30 degrees to the surface of the arm and was not inserted too deeply. When the 
last tube was full, the tourniquet and needle were quickly removed from the donor's arm. 
Gauze was immediately placed the on the puncture site and sufficient pressure was 
maintained to avoid the formation of a hematoma. After maintaining a pressure for 1-2 
minutes, a new gauze or Band-Aid was applied to the puncture site. 
2.2.3. Isolation procedure of peripheral blood mononuclear cells (PBMCs) 
Blood samples were taken from healthy nonsmokers and smokers (9 mL each donor) and 
then were transferred into 15 ml Falcon tubes with 6 ml lymphocyte separation medium 
1077 (LSM) per each tube. The handling should be very careful to make sure the blood 
flows gently above the LSM. Density gradient centrifugation was performed at 1000 g 
for 20 min at 4°C without brake (Thermo Scientific). The PBMC layer was transferred to 
a new Falcon tube and washed twice with PBS (centrifugation at 600 g for 10 min at 4 °C). 
The blood plasma was transferred into a fresh Eppendorf tube to obtain a fetal calf serum 
(FCS) alternative, then centrifuged for 10 min at 10,000 g to get rid of pellet thrombocytes. 
The supernatant was discarded, and the pellet was re-suspended in 10 mL RPMI 1640 
culture medium (Fuss et al., 2009).  
2.2.4. Cell counting and diluting      
The coverslip on the hemocytometer was cleaned with ethanol 70%. The two bars of the 
hemocytometer were breathed on and the cover glass was put on. The cell suspension was 
thoroughly mixed, take out 10 µl from the PBMC solution and mix it with 10 µl trypan 
blue working solution. Afterwards, 10 µl of the mixture was transferred into each 
counting chamber. The cells in the four counting grids were counted and the average was 
calculated. Total number of cells = n * Vf * V * 104 (n: average of counted cells, Vf: 
dilution factor, V: volume of cell suspension (here it’s 10 ml), and 104: factor of the cell 
count chamber). The PBMC suspension was then diluted into different volumes in order 
to make the concentration of each new suspension 5*105 cell/ml. 
2.2.5. Preparation of inactivated bacteria  
The Institute of Medical Microbiology and Hygiene in Tübingen University has provided 
us with four inactivated bacteria (S. a., S. e., P. a., E. f.) that were prepared by heating 
method (Donkor et al., 2012), also known as pasteurization (Taddese et al., 2018). In the 
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food industry, pasteurization can preserve products for a long time while avoiding the 
destruction of essential nutrients. The mechanism of pasteurization inactivating bacteria 
is to raise the temperature up to 70 ° C for utmost 30 minutes to denature bacterial cell 
membranes and proteins (Plovier et al., 2017).  
2.2.6. Incubation 
For incubation, 2% plasma or 2% FCS (Chen et al., 2014) was added to each PBMC 
suspension. After that, each PBMC suspension was divided into 5 treatment conditions 
as follows: the first condition had nothing added; the second condition had heat 
inactivated S. a. 4 µl/ml added; the third condition had heat inactivated S. e. 2 µl/ml added; 
the fourth condition had heat inactivated P. a. 2 µl/ml added; the fifth condition had heat 
inactivated E. f. 1 µl/ml added. Each treatment condition was put into incubator for 24 h 
(Donkor et al., 2012). 
2.2.7. Human Cytokine Antibody Array 
Cytokine array kits were performed as described by the manufacture. Briefly, components 
were removed from storage and the components were equilibrated to room temperature. 
Antibody arrays were carefully removed from the plastic package and each membrane 
(printed side up) was placed into a well of the incubation tray (one membrane per well). 
A total of 2 ml of blocking buffer was pipetted into each well and was incubated for 30 
minutes at room temperature. Blocking buffer was aspirated from each well with a pipette. 
A 1 ml sample was pipetted into each well and was incubated for 1.5 h at room 
temperature. Then, samples were aspirated from each well with a pipette. A total of 2 ml 
of wash buffer I was pipetted into each well and was incubated for 5 minutes at room 
temperature (washed 3 times). Then, 2 ml of wash buffer II was pipetted into each well 
and was incubated for 5 minutes at room temperature (washed 2 times). A total of 1 ml 
of the prepared biotinylated antibody cocktail was pipetted into each well and was 
incubated for 1.5 to 2 h at room temperature. Then, the biotinylated antibody cocktail was 
aspirated out from each well, and the membranes were washed wash buffer I and II as 
mentioned above. Then, a total of 2 ml of HRP-Streptavidin was pipetted into each well 
and was incubated for 2 h at room temperature. HRP-Streptavidin was aspirated out from 
each well, and the membranes were washed as above. Membranes were placed on the 
chromatography paper, and the surplus wash buffer was discarded from the membrane 
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with tissue paper. A total of 500 µl detection buffer mixture was pipetted into each 
membrane as was incubated for 2 minutes at room temperature. The membranes were 
covered with another plastic sheet and transferred to the chemiluminescence imaging 
system (ChemoCam, Intas) to be measured.        
2.2.8. Enzyme-linked immunosorbent assay (ELISA) 
Standard ABTS ELISA development kits were purchased from PeproTech, Inc, USA and 
the ELISAs performed as described by the manufacture. Conditions are described in 
Table 1. Before being added to the plate wells, each of the captured antibodies, standard 
antigens, and detection antibodies were diluted 100 times with different dilute as shown 
in Table 2. Meanwhile, the Avidin-HRP conjugate was diluted 2,000 times. The specific 
information of the ABTS reaction solution is shown in Table 3.  
Table 5. Overview of stock reagents of different cytokines  
Cytokine Captured 
antibody  
Standard antigen Detection 
antibody 
IFN-γ 100 µg/ml 1 µg/µl 100 µg/ml 
TNF-α 100 µg/ml 1 µg/µl 50 µg/ml 
IL-1β 100 µg/ml 0.5 µg/µl 100 µg/ml 
IL-4 100 µg/ml 1 µg/µl 100 µg/ml 
IL-6 100 µg/ml 1 µg/µl 100 µg/ml 
IL-10 100 µg/ml 1 µg/µl 50 µg/ml 
IL-12 100 µg/ml 1 µg/µl 100 µg/ml 
A total of 50 µl captured antibody dilution was pipetted to each well of the 96-well plate 
and was incubated at room temperature (20–25 °C) overnight. The plate was washed three 
times (each used well was filled with 120 µl washing buffer, and the washing buffer was 
removed by tapping the plate onto absorbent material). A total of 100 µl blocking solution 
was added to each well and was incubated (20–25 ℃) for one h by shaking. The plate 
was washed one time (as described above). A total of 50 µl standard (S1–S8) or sample 
was pipetted to each well and was incubated (20–25 °C) for 2 h by shaking. The plate 
was washed 4 times (as described above). A total of 50 µl detection antibody dilution was 
added to each well and was incubated (20–25 °C) for 2 h by shaking. The plate was 
washed for 4 times (as described above). A total of 50 µl Avidin-HRP conjugate dilution 
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was pipetted to each well and was incubated at room temperature (20–25 °C) for 30 
minutes by shaking. The plate was washed 4 times (as described above). Finally, 50 µl of 
ABTS reaction solution was added to each well and was incubated for 1 h. The 
absorbance was measured in an omega plate reader (Fluostar Omega, BMG Labtech 
GmbH) at 405 nm - 650 nm. 
2.2.9. Test that cytokines are mainly released by PBMCs in the whole blood. 
In most studies, PBMCs isolated from blood were used to investigate the production of 
cytokines in vitro (Le Meur et al., 1999), so it was speculated that cytokines are mainly 
produced by PBMC. The following test shall verify this hypothesis: whole blood was 
collected from 3 healthy nonsmokers and 2 healthy smokers, with 10 ml blood (one tube) 
per donor. Each 10 ml blood sample was divided into two parts: one part (9.7 ml) was 
used to isolate PBMCs and the other part (0.3 ml) was maintained as whole blood. The 
0.3 ml whole blood sample was diluted to 1.5 ml after adding 1.2 ml PBS. PBMCs pellets 
were isolated from the 9.7 ml blood sample and then suspended in 1.5 ml RPMI, and 2% 
plasma was added to the new PBMC suspension. Both the whole blood solution and 
PBMCs solution of each donor were incubated for 24 h before being centrifuged. The 
supernatants were used as samples in ELISA measurements. 
2.2.10. Find out the appropriate concentration of each of the four types of 
inactivated bacteria.  
In the study conducted by Katial et al., the concentration for S. a. was 10 µg/ml (Katial 
et al., 1998). However, with one Eppendorf tube per each type of bacterium, their 
amounts were not sufficient. Furthermore, their potency was not quite clear. On account 
of the frequent consuming of the four types of bacteria in the future experiments, the 
efficient concentration of each of the four types of bacteria was investigated. Two 
different concentration gradients, 2 µl/ml and 4 µl/ml, were set for each type of inactivated 
bacterium that was added to the PBMCs suspension.   
Blood was taken from four new healthy nonsmoking donors, and the PBMCs were 
isolated. The PBMCs suspension was obtained according to the method referred to above. 
Each donor’s PBMC suspension was mixed with 2% plasma and then was equally divided 
into ten parts: control, S. a. 2 µl/ml, S.a. 4 µl/ml, S. e. 2 µl/ml, S. e. 4 µl/ml, P. a. 2 µl/ml, 
P. a. 4 µl/ml, E. f. 2 µl/ml, and E. f. 4 µl/ml. All the conditions were incubated for 24 h 
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before they were centrifuged to acquire the supernatants that were used as samples in 
ELISA measurements. 
2.2.11. Set the suitable concentration of PBMCs. 
Since the concentration of inactivated bacteria had been determined, the next step was to 
determine the concentration of the PBMCs. The PBMCs concentrations used in previous 
publications were 5×105 cells/ml (Katial et al., 1998), 40×105 cells/ml (Ngkelo et al., 
2012), 50×105 cells/ml (Friberg et al., 1994), 80×105 cells/ml (Corry et al., 1996) and 
200×105 cells/ml (Jeurink et al., 2008). However, our blood donation is not enough to 
reach such a high concentration, so we tried to use a lower concentration. Two 
concentrations, 5×105 cells/ml and 2.5×105 cells/ml, were selected for the PBMCs. The 
amounts of cytokine (IFN-γ) secreted by the PBMCs were measured within these two 
selected concentration groups.  
Blood was taken from four new healthy nonsmoking donors, and the PBMCs were 
isolated. After counting the PBMCs under the microscopy and re-diluting them to 5×105 
cells/ml and 2.5×105 cells/ml for each donor, the final PBMCs suspensions were obtained. 
Each PBMCs suspension was mixed with 2% plasma. Each donor’s new PBMCs 
suspension was equally divided into five parts: control, S. a. 4 µl/ml, S. e. 2 µl/ml, P. a. 2 
µl/ml, and E. f. 1 µl/ml. All the ten conditions were incubated for 24 h before they were 
centrifuged to separate the supernatants that were used as samples in ELISA 
measurements. 
2.2.12. Cytokine array of various cytokine levels released by PBMCs between 
nonsmokers and smokers stimulated by four types of inactivated bacteria.  
Blood was taken from four new healthy non-smoking donors, and the PBMCs were 
isolated. The final PBMCs suspension was obtained after counting the cells in the 
microscopy and re-diluting them to 5×105 cells/ml for each donor. Each donor’s PBMCs 
suspension was mixed with 2% plasma and then was equally divided into five parts: 
control, S. a. 4 µl/ml, S. e. 2 µl/ml, P. a. 2 µl/ml, and E. f. 1 µl/ml. All 40 conditions (5 
conditions per donor) were incubated for 24 h before they were centrifuged to acquire the 
supernatants that were used as samples in cytokine arrays.  
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2.2.13. ELISA of anti-inflammatory and pro-inflammatory cytokine levels released 
by PBMCs between nonsmokers and smokers stimulated by four types of 
inactivated bacteria were measured and the effect of plasma was checked.  
The cytokine array demonstrated that IL-10 and IL-4 (both of which have anti-
inflammatory properties) were higher in PBMCs of smokers than in nonsmokers whether 
or not bacteria are present. Since these anti-inflammatory cytokines have been promoted 
by smoking, we postulated that pro-inflammatory cytokines should be reduced. ELISA 
was performed to investigate this change. Blood was taken from new healthy nonsmoking 
donors and healthy smoking donors (4 smokers and 4 nonsmokers every time), and the 
PBMCs were isolated. The final PBMCs suspension was obtained after counting the cells 
in the microscopy and re-diluting them to 5×105 cells/ml for each donor. Each donor’s 
PBMCs suspension was divided into two parts, one mixed with 2% plasma (the donor’s 
own plasma) and the other mixed with 2% FCS. Then, each new PBMCs suspension was 
continuously equally divided into five parts: control, S. a. 4 µl/ml, S. e. 2 µl/ml, P. a. 2 
µl/ml, and E. f. 1 µl/ml. Thus, each donor had ten conditions: control with plasma, control 
with FCS, S.a. with plasma, S. a. with FCS, S. e. with plasma, S. e. with FCS, P. a. with 
plasma, P. a. with FCS, E. f. with plasma, and E. f. with FCS. All the PBMCs suspension 
conditions were incubated for 24 h before they were centrifuged; supernatants that were 
used as samples in ELISA measurements (Figure 5). 
 
Figure 5. Schematic diagram of measurement of cytokines secreted by PBMCs stimulated 
with four types of inactivated bacteria.  
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Each smoking and nonsmoking donor’s PBMCs suspension was divided into two parts, 
one mixed with plasma and the other mixed with FCS, which aimed at eliminating the 
effect of plasma. The PBMCs suspensions were continuously stimulated with different 
types of inactivated bacteria and were incubated for 24 h before they were centrifuged to 
separate the supernatants. ELISA and cytokine array were performed using the 
supernatants. 
2.2.14. Determine the appropriate concentration of HaCaT cells that have just 
reached cell confluence.  
In order to grow HaCaT cells into 100% confluence in 24 h, Wang et al. used a 
concentration of 6×105 cells/mL in his study (Wang et al., 2016). This concentration is 
confirmed again before use in our experiment. After culture and sub-culture, the HaCaT 
cells were seeded into the 96-well plate with concentration gradients as follows: 0/100 µl, 
10 000 cells/100 µl, 20 000 cells/100 µl, 30 000 cells/100 µl, 40 000 cells/100 µl, 50 000 
cells/100 µl, 60 000 cells/100 µl, and 80 000 cells/100 µl. After incubating the plate in 
the incubator (37 °C, 5% CO2) for 24 h, the confluence of each concentration condition 
was examined by microscope and the Resazurin assay and SRB assay were performed to 
test the viability.  
2.2.15. Resazurin assay and Sulforhodamine B (SRB) staining 
Resazurin that is a redox-sensitive dye that can be transformed by mitochondria to 
become resorufin, both of which can be measured via the fluorescence (McMillian et al., 
2002). Resazurin conversion could reflect the viability, cytotoxicity, proliferation in 
cultured cells (Anoopkumar-Dukie et al., 2005). The mechanism of SRB staining is that 
SRB can bind to surface proteins in acidic environment, so it could be used to measure 
the cell density (Skehan et al., 1990). SRB staining is independent of metabolic activity 
in cells (Vichai and Kirtikara, 2006), therefore the combined use of SRB staining and 
resazurin assay in our experiment. After removal of the culture medium from cells, 10 µl 
Resazurin working solution was added to each well and was incubated in an incubator 
(37 °C, 5% CO2) for 30 minutes, followed by complete fluorescence measurement and 
calculation.   
After removal of the culture medium from cells, the cells were covered with 99% ethanol 
(100 µl per well) and frozen at -20 °C for 1 h. Then, the cells were removed from the 
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ethanol. The cells were washed once with tap water and left to air- dry on plates. The cells 
were covered with SRB Solution (50 µl per well) and incubated for 30 min at room 
temperature by shaking (to protect from light). Then, the cells were removed from the 
SRB solution. To remove unbound SRB, the cells were washed 3–4 times with 1% acetic 
acid solution (stop when no pink stain resolves anymore). For quantification, SRB was 
resolved with 10 mM unbuffered TRIS solution (100 µl per well), followed by complete 
absorbance measurement and calculation. 
2.2.16. HaCaT cells Migration Assay  
HaCaT cells migration assay was performed to mimic the wound healing process in vitro 
(Kramer et al., 2013). What role the IL-4 played in HaCaT cells migration was topic in 
our experiment. The treatment groups were stimulated by a supernatant of PBMCs (with 
FCS) stimulated by four types of inactivated bacteria (S. a., S. e., P. a., and E. f.) from 
smokers and nonsmokers, which was used in ELISAs. The positive control group was 
stimulated by FCS with IL-4, while the negative control group was stimulated by FCS 
without IL-4. 
A 96-well plate was taken out from refrigeration to the lab bench. Stoppers were seeded 
in the plate to ensure that stoppers were securely sealed against the bottom of the plate. 
A total of 100 µl suspended cells 60,000 cells/well (100 µl) were pipetted into each test 
well through one of the side ports of the stopper and gently tapped to evenly distribute 
the content of each well. The stoppers were removed after incubating for 24 h. The 
medium was removed with a pipette, and the wells were gently washed with 100 µl PBS 
to remove any unattached cells. A total of 50 µl HaCaT medium was added into each of 
the wells. Then, 50 µl ELISA supernatant was added into each different treated well, 50 
µl RPMI + 2%FCS was added into each negative control well, and 50 µl RPMI + 2% FCS 
plus IL-4 (5 ng/ml) was added into each positive control well. A picture was taken under 
the microscope to get the baseline picture, and the contents were allowed to continue to 
incubate for 24 h. At which time, another picture was taken under the microscope to get 
the 24 h point picture (Figure 6).  
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Figure 6. HaCaT cells were stimulated with supernatant of PBMCs. 
HaCaT cells of 0 point were stimulated by PBMCs with FCS supernatant stimulated by 
four types inactivated bacteria (S. a., S. e., P. a., and E. f.), which were used in ELISAs. 
The 0 point area and 24 h point area were measured. 
After collection of images, the image analysis was performed by using the software 
TScratch. For each condition well, the migration rate was calculated by the function 
(Figure 8) as follows: 
 
Figure 6. The sketch of migration function by which the migration rate of each group was 
calculated.  
Function: (0 point area- 24 h point area)/ 0 point area ×100%. 
2.3 Statistical Analysis 
Statistical analysis was performed with GraphPad Prism Version 7 with one-way 
ANOVA (nonparametric) multiple comparisons and mean ranks of preselected pairs of 
columns. Based on the choices, Prism performed the Kruskal-Wallis test or Dunn’s 
multiple comparisons test. Differences in comparison were considered statistically 
significant at values of *P < 0.05; ***P < 0.0005. After each data analysis was completed, 
it was discussed with PD Dr. Sabrina Ehnert. 
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3. Result  
3.1. Cytokines were mainly secreted by PBMCs rather than the other cells in the 
blood. 
The result demonstrated (as below in Figure 7) that the PBMCs mainly secrete the 
cytokines (IFN-γ). Isolated PBMCs secreted significantly more cytokines (IFN-γ) than 
whole blood. 
 
Figure 7. ELISA experiment showed that cytokines (IFN-γ) were mainly secreted by 
PBMCs rather than other cells in the whole blood. 
Both whole blood and PBMCs solution of each sample were incubated for 24 h before 
the supernatant was acquired by centrifugation. The cells number in whole blood group 
is 300 times that of the cells number in PBMC group. However, the IFN-γ released in 
PBMC group was significantly higher than in whole blood cells. Each point represents 
the mean ± standard deviation (SD) error bars of five donors (three nonsmokers and two 
smokers) from duplicate experiments. ***P < 0.0005 (PBMCs versus Whole blood). 
3.2. The appropriate concentration the four types of inactivated bacteria are S.a. 4 
µl/ml, S.e. 2 µl/ml, P.a. 2 µl/ml, and E.f. 1 µl/ml.   
The result demonstrated (as below in figure 8) that we decided to use S. a. 4 µl/ml, S. e. 
2 µl/ml, P.a. 2 µl/ml, and E. f. 1 µl/ml during the following research. The normalized 
result of the INF-γ ELISA experiment shows that S. a. 4 µl/ml could stimulate PBMCs to 
secrete insignificantly more INF-γ than S. a. 2 µl/ml. Besides, S. e. 2 µl/ml could stimulate 
PBMCs to secrete insignificantly more INF-γ than S. e. 4 µl/ml. Furthermore, both E. f. 2 
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µl/ml and E. f. 4 µl/ml could stimulate PBMCs to secrete much more INF-γ. However, 
there was no significant difference between the two concentration gradients of P.a.  
 
Figure 8. Two ELISA experiments have been done in order to check the suitable 
concentration of the four kinds of inactivated bacteria. 
ELISA showed that PBMCs stimulated with S. a. 4 µl/ml produced significant more IFN-
γ than PBMCs stimulated with S. a. 2 µl/ml. However, there were no significant 
difference calculated among the three comparisons: S. e. 2 µl/ml versus S. e. 4 µl/ml, P.a. 
2 µl/ml versus P.a. 4 µl/ml, and E. f. 2 µl/ml versus E. f. 4 µl/ml. Each point represents 
the mean ± SD error bars of four healthy nonsmoking donors from duplicate experiments. 
Statistical significance is indicated by *P < 0.05; ***P < 0.0005 (S. a. 4 ul/ml versus S. 
a. 2 ul/ml). 
3.3. The suitable concentration of PBMCs is 5×105 cells/ml 
After the ELISA experiments, the result demonstrated (as below in Figure 9) that the 
5×105 cells/ml PBMCs could produce more cytokines (IFN-γ) than the 2.5×105 cells/ml 
PBMCs in each of the four conditions. Therefore, 5×105 cells/ml will be fixed as the 
concentration of PBMCs in the following experiment. 
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Figure 9. ELISA experiment shows that the 5×105 cells/ml PBMCs could produce more 
IFN-γ than the 2.5×105 cells/ml PBMCs for each condition, with however insignificant 
differences. 
In both 5×105 cells/ml PBMCs group and 2.5×105 cells/ml PBMCs group, there were five 
sub-groups: the control sub-group with nothing added and four types of inactivated 
bacteria sub-groups were respectively set as S. a. 4 µl/ml, S. e. 2 µl/ml, P. a. 2 µl/ml, and 
E. f. 1 µl/ml. ELISA showed that 5×105 cells/ml PBMCs could produce in significantly 
more cytokines (IFN-γ) than the 2.5×105 cells/ml PBMCs could for each condition. Each 
point represents the mean ± SD error bars of four healthy nonsmoking donors from 
duplicate experiments.  
3.4. Cytokine arrays: anti-inflammatory cytokines secreted by PBMCs from 
smokers were higher than from nonsmokers  
The result of cytokine arrays of the various cytokine levels released by the PBMCs 
between nonsmokers and smokers stimulated by four types of inactivated bacteria are 
shown in Figure 10.   
The basal anti-inflammatory cytokines IL-10 and IL-4, were higher in smokers than in 
nonsmokers.   
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Figure 10. Cytokine arrays were applied to verify the cytokines secreted by PBMCs 
between nonsmokers and smokers stimulated by the four types of inactivated bacteria. 
There were 74 kinds of cytokines that have been checked (A. 37 kinds of cytokines and B. 
37 kinds of cytokines). IL-10 and IL-4 were higher expressed in smokers than in 
nonsmokers. The concentration of PBMCs among each condition is 5×105 cells/ml (2% 
plasma). The control group with nothing added and four types of inactivated bacteria 
groups were respectively set as S. a. 4 µl/ml, S. e. 2 µl/ml, P.a. 2 µl/ml, and E. f. 1 µl/ml. 
Each colour unit represents the condition sample pool combined by four donors. Three 
colour gradation: green set as 0.2, black set as 1, and red set as 5. 
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3.5. Cytokine levels released by PBMCs between nonsmokers and smokers among 
four types of inactivated bacteria condition were measured and the effect of 
plasma was checked. 
3.5.1. Anti-inflammatory cytokines 
3.5.1.1. IL-4 
The result of the IL-4 ELISA experiment is demonstrated below in Figure 11. The graph 
A and graph B were drawn from the same data according to different grouping methods 
(graph A was grouped by different inactivated bacteria, while graph B was grouped by 
smoking or not). In figure 11-A, among the four control groups (nonsmokers Plasma-
control, nonsmokers FCS-control, smokers Plasma-control and smokers FCS-control 
groups), the IL-4 level in the smokers FCS-control group was significantly higher than in 
the nonsmokers FCS-control group. When stimulated by S. a., the PBMCs (incubated 
with FCS) from smokers produced significantly more IL-4 than the PBMCs (both with 
Plasma and FCS) from nonsmokers. Similarly, the PBMCs (incubated with FCS) that 
were stimulated by P. a. from smokers produced significantly more IL-4 than the PBMCs 
(both with Plasma and FCS) from nonsmokers. In addition, when stimulated by E. f., the 
PBMCs (incubated with FCS) from smokers produced significantly more IL-4 than the 
PBMCs (with Plasma) from nonsmokers. Nevertheless, when treated with S. e., he 
PBMCs (both plasma and FCS) from smokers and PBMCs (both Plasma and FCS) from 
nonsmokers did not display significant difference in producing IL-4.  
In figure 11-B, within each of the nonsmokers Plasma group, nonsmokers FCS group, 
smokers Plasma group, and smokers FCS group, when treated with the four types of 
inactivated bacteria respectively; the PBMCs did not produce significantly more IL-4 
compared their own control group. There was a trend that the reaction of PBMC from 
nonsmokers to inactivated bacteria was more intensive than that from smokers. 
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Figure 11. IL-4 released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The incubation time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus 
epidermidis 2 µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), and E. f. (Enterococcus 
faecalis 1 µl/ml). Each point represents the mean ± standard error of the mean (SEM) 
error bars of four healthy nonsmoking or smoking donors from duplicate experiments. 
Statistical significance is indicated by *P < 0.05; ***P < 0.0005 in one-way ANOVA 
(nonparametric) multiple comparisons. 
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3.5.1.2. IL-10 
The result of the IL-10 ELISA experiment is demonstrated below in Figure 12. In figure 
12-A, without the stimulation of inactivated bacteria, the PBMCs from smokers produced 
higher levels of IL-10. Although insignificant, this trend was clear. There was no 
significant difference in IL-10 between the nonsmokers Plasma-S. a. group and the 
smokers Plasma-S. a. group. Likewise, when treated with the other three types of 
inactivated bacteria (S. e., P. a. and E. f.), respectively, the PBMCs from smokers and 
PBMCs from nonsmokers did not display significant difference in producing IL-10. 
There is a trend that the PBMCs could produce relatively more IL-10 when stimulated by 
smoking.   
In figure 12-B, as for the nonsmokers Plasma group, all the nonsmokers Plasma treatment 
groups’ PBMCs produced insignificantly more IL-10 than their own control group. 
Besides, when treated with the four types of inactivated bacteria, the PBMCs from 
smokers produced significantly less IL-10 than their own control group.  
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Figure 12. IL-10 released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The concentration of PBMCs among each condition is 5×105 cells/ml. The incubation 
time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus epidermidis 2 
µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), and E. f. (Enterococcus faecalis 1 µl/ml). 
A and B were drawn from the same data according to different grouping methods (A was 
grouped by different inactivated bacteria, while B was grouped by smoking or not). Each 
point represents the mean ± SEM error bars of 8 healthy nonsmoking or smoking donors 
from duplicate experiments. There is no significant difference calculated in one-way 
ANOVA (nonparametric) multiple comparisons.  
3.5.1.3. IL-12  
For the IL-12 ELISA experiment, the result is shown in Figure 13. In figure 13-A, among 
the four control groups: nonsmokers Plasma-control group, nonsmokers FCS-control 
group, smokers Plasma-control group and smokers FCS-control group, there was no 
significant difference in IL-12 levels. When treated with the four types of inactivated 
bacteria (S. a., S. e., P.a. and E. f.), respectively, the PBMCs (both Plasma and FCS) from 
smokers and PBMCs (both Plasma and FCS) from nonsmokers did not display significant 
difference in producing IL-12.  
In figure 13-B, within each of the three large groups (the nonsmokers Plasma group, 
smokers Plasma group, and smokers FCS group), when treated with the four kinds of 
inactivated bacteria, the PBMCs produced insignificantly more TNF-α than the PBMCs 
in their own control group. However, within the nonsmokers-FCS group, the PBMCs 
stimulated with P. a. produced a significantly higher level of IL-12 than in its own control 
group. There is also a trend that the reaction of PBMCs from nonsmokers to inactivated 
bacteria is significantly more strong than that from smokers. 
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Figure 13. IL-12 released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The incubation time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus 
epidermidis 2 µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), and E. f. (Enterococcus 
faecalis 1 µl/ml). Each point represents the mean ± SEM error bars of 12 healthy 
nonsmoking or smoking donors from duplicate experiments. A and B were drawn from 
the same data according to different grouping methods (A was grouped by different 
inactivated bacteria, while B was grouped by smoking or not). Statistical significance is 
indicated by *P < 0.05(nonsmokers FCS-P. a. subgroup versus nonsmokers FCS-control 
subgroup). 
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3.5.2. Pro-inflammatory cytokines 
3.5.2.1. IL-1β 
For the IL-1β ELISA experiment, the result is shown below in Figure 14. In figure 14-A, 
among the four control groups (nonsmokers Plasma-control group, nonsmokers FCS-
control group, smokers Plasma-control group and smokers FCS-control group), there was 
also no significant difference in IL-1β levels. When treated with the four types of 
inactivated bacteria (S. a., S. e., P.a. and E. f.), the PBMCs (both Plasma and FCS) from 
smokers and PBMCs (both Plasma and FCS) from nonsmokers did not display significant 
difference in producing IL-1β.  
In figure 14-B, within the nonsmokers Plasma group, the nonsmokers Plasma-S. e. group 
and nonsmokers Plasma-P.a. group PBMCs produced significantly more TNF-α 
compared to their own control group. Within the nonsmokers FCS group, when treated 
with the four kinds of inactivated bacteria, all the nonsmokers FCS treatment group 
PBMCs, except nonsmokers FCS-S. a. group, produced significantly more IL-1β than 
their own control group. However, within each of the two large smoking groups: the 
smokers Plasma group, and smokers FCS group, when treated with the four kinds of 
inactivated bacteria, the PBMCs produced insignificantly more IL-1β than in their own 
control group. There was a trend that the reaction of PBMCs from nonsmokers to 
inactivated bacteria was significantly more strong than that from smokers.  
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Figure 14. IL-1β released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The incubation time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus 
epidermidis 2 µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), and E. f. (Enterococcus 
faecalis 1 µl/ml). A and B were drawn from the same data according to different grouping 
methods (A was grouped by different inactivated bacteria, while B was grouped by 
smoking or not). Each point represents the mean ± SEM error bars of 8 healthy 
nonsmoking or smoking donors from duplicate experiments. Statistical significance is 
indicated by *P < 0.05; ***P < 0.0005 in one-way ANOVA (nonparametric) multiple 
comparisons.  
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3.5.2.2. TNF-α 
The result of the TNF-α ELISA experiment is demonstrated below in Figure 15. In figure 
15-A, there was no significant difference in TNF-α levels among the following four 
control groups: nonsmokers Plasma-control, nonsmokers FCS-control, smokers Plasma-
control and smokers FCS-control groups. When treated with the four types of inactivated 
bacteria (S. a., S. e., P.a. and E. f.), respectively, the PBMCs (both Plasma and FCS) from 
smokers and PBMCs (both Plasma and FCS) from nonsmokers did not display significant 
difference in producing TNF-α.  
In figure 15-B, as for the nonsmokers Plasma group, when treated with the four types of 
inactivated bacteria, all the nonsmokers Plasma treatment group PBMCs, except 
nonsmokers Plasma-S. e. group, produced much more TNF-α than the nonsmokers 
Plasma-control group. However, in the smoker Plasma group, when treated with the four 
kinds of inactivated bacteria, all the smokers Plasma treatment group PBMCs did not 
produce significantly more TNF-α than the smokers Plasma-control group. As for the 
nonsmokers-FCS group, when treated with the four kinds of inactivated bacteria, all the 
nonsmokers FCS treatment group PBMCs produced much more TNF-α than the 
nonsmokers FCS-control group. However, in the smokers-FCS group, when treated with 
the four kinds of inactivated bacteria, all the smokers FCS treatment group PBMCs also 
did not produce significantly more TNF-α than the smokers FCS-control group. The trend 
that the reaction of PBMCs from nonsmokers to inactivated bacteria is significantly more 
intensive than that from smokers was clear.  
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Figure 15. TNF-α released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The incubation time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus 
epidermidis 2 µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), and E. f. (Enterococcus 
faecalis 1 µl/ml). A and B were drawn from the same data according to different grouping 
methods (A was grouped by different inactivated bacteria, while B was grouped by 
smoking or not). Each point represents the mean ± SEM error bars of 16 healthy 
nonsmoking or smoking donors from duplicate experiments. Statistical significance is 
indicated by *P < 0.05; ***P < 0.0005 in one-way ANOVA (nonparametric) multiple 
comparisons. 
3.5.2.3. IFN-γ 
For the IFN-γ ELISA experiment, the result is demonstrated below in Figure 16. In figure 
16-A, among the nonsmokers Plasma-control group, nonsmokers FCS-control group, 
smokers Plasma-control group and smokers FCS-control group, the four control groups, 
there was no significant difference in IFN-γ levels. When stimulated with S. a., PBMCs 
with FCS from nonsmokers produced higher level of IFN-γ than PBMCs with Plasma 
from nonsmokers. When treated with the other three types of inactivated bacteria (S. e., 
P.a. and E. f.), respectively, the PBMCs (both Plasma and FCS) from smokers and 
PBMCs (both Plasma and FCS) from nonsmokers did not display significant difference 
in producing IFN-γ. 
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In figure 16-B, for the each of the four groups (nonsmokers Plasma, nonsmokers FCS, 
smokers Plasma, and smokers FCS), when treated with the four kinds of inactivated 
bacteria, all the treatment group PBMCs did not produce significantly different IFN-γ 
levels from its own control group.  
 
 
Figure 16. IFN-γ released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The incubation time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus 
epidermidis 2 µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), and E. f. (Enterococcus 
faecalis 1 µl/ml). A and B were drawn from the same data according to different grouping 
methods (A was grouped by different inactivated bacteria, while B was grouped by 
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smoking or not). Each point represents the mean ± SEM error bars of 12 healthy 
nonsmoking or smoking donors from duplicate experiments. Statistical significance is 
indicated by *P < 0.05 (nonsmokers FCS-S. a. sub-group versus nonsmokers Plasma- S. 
a. sub-group). 
3.5.2.4. IL-6 
For the IL-6 ELISA experiment, the result is demonstrated below in Figure 17. In figure 
17-A, among the four control groups (nonsmokers Plasma-control, nonsmokers FCS-
control, smokers Plasma-control and smokers FCS-control group), there was also no 
significant difference in IL-6 levels. When treated with the four types of inactivated 
bacteria (S. a., S. e., P.a. and E. f.), respectively, the PBMCs (both Plasma and FCS) from 
smokers and PBMCs (both Plasma and FCS) from nonsmokers did not display significant 
difference in producing IFN-γ.  
In figure 17-B, as for the smokers Plasma group, when treated with the four types of 
inactivated bacteria, PBMCs in smokers Plasma-E. f. group, produced much more IL-6 
than its own control group. In the smoker FCS group, when treated with the four kinds of 
inactivated bacteria, PBMCs from smokers FCS-P. a. group and smokers FCS-E. f. group 
produce significantly more IL-6 than their own control group. However, as for 
nonsmoking groups (nonsmokers Plasma group, nonsmokers-FCS group), when treated 
with the four kinds of inactivated bacteria, PBMCs did not produce significantly more 
IL-6 than their own control group. 
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Figure 17. IL-6 released by PBMCs from nonsmokers and smokers stimulated by four 
types of inactivated bacteria. 
The incubation time is 24 h. S. a. (Staphylococcus aureus 4 µl/ml), S. e. (Staphylococcus 
epidermidis 2 µl/ml), P. a. (Pseudomonas aeruginosa 2 µl/ml), E. f. (Enterococcus 
faecalis 1 µl/ml). A and B were drawn from the same data according to different grouping 
methods (A was grouped by different inactivated bacteria, while B was grouped by 
smoking or not). Each point represents the mean ± SEM error bars of 8 healthy 
nonsmoking or smoking donors from duplicate experiments. Statistical significance is 
indicated by *P < 0.05; ***P < 0.0005 in one-way ANOVA (nonparametric) multiple 
comparisons. 
 
3.6. The appropriate concentration of HaCaT cells was 60,000 cells/well.  
In order to ensure that the number of cells in each well in the following migration assay 
is the same and that at this number the cells were just enough to achieve confluence, we 
perform concentration-confluence experiment to determine this number. The result of the 
HaCaT cell concentration-confluence experiment showed that as the cell concentration is 
increased, the cells is grow to the confluence state. Only when the cells concentration 
reached 60,000 cells/well, could there be a confluence among the cells at the bottom of 
the well (Figure 18).  
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Figure 18. HaCaT cells cultured at different cell densities onto a 96-well plate to generate 
appropriate concentration that have just reached cell confluence. 
The concentration gradient was set as follows: A. 10,000 cells/100 µl, B. 20,000 cells/100 
µl, C. 30,000 cells/100 µl, D. 40,000 cells/100 µl, E. 50,000 cells/100 µl, F. 60,000 
cells/100 µl, and G. 80,000 cells/100 µl. 
 
3.7. IL-4 repressed the migration of HaCaT cells in Migration Assay 
In order to determine whether IL-4 promotes or inhibits wound healing, the HaCaT cells 
migration assay had been performed. Each treatment group was used with PBMCs (FCS) 
supernatant, which were used in ELISAs. Seven nonsmoking supernatant samples and 
seven smoking supernatant samples were used in the migration assay with four times. 
Both the 0 point area and 24 h point area of the groups with nonsmokers (NS) PBMCs 
with FCS stimulated by four types inactivated bacteria (S. a., S. e., P. a., and E. f.) and 
smokers (S) PBMCs with FCS stimulated by four types inactivated bacteria (S. a., S. e., 
P. a., and E. f.) was measured (Figure 19). 
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Figure 19. The baseline condition (0 point) and migrated condition (24 h point) of each 
group had been measured with T-scratch software. 
NS: nonsmokers, S: smokers, Neg: negative, and Pos: positive.  
 
The migration rate of each group was calculated using the migration function: (0 point 
area - 24 h point area)/0 point area ×100%. The result is shown below in Figure 20.  
In Figure 20-A, the migration rate of the positive control group was the lowest among all 
the groups, and the migration rate of the negative control group, which was free from IL-
4, was significantly higher than that of the positive group. It indicates that IL-4 had a 
negative effect on the movement of HaCaT cells and accordingly would inhibit the wound 
healing. All the inactivated bacteria stimulated groups nonsmokers large group had 
significantly higher migration rates than the positive control group. Furthermore, the 
migration rates in the nonsmokers inactivated bacteria stimulated groups were higher than 
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in smokers inactivated bacteria stimulated groups. Of particular note, the migration rate 
of the nonsmoking P. a. group was significantly higher than that of the smoking P. a. 
group (Figure 20-C). Besides, within the NS group, all the inactivated bacteria stimulated 
groups had insignificantly higher migration rates than their own control group (Figure 
20-B). As the IL-4 level in smoking inactivated bacteria treated groups were higher than 
that in nonsmoking inactivated bacteria treated groups, which had been confirmed in the 
ELISA above, this can further explain to some extent why smoking is not conducive to 
wound healing. 
 
Migration rate (%) (N=14, n=2) 
 
Figure 20. IL-4 decreased the migration rate and the migration rate in smoking group was 
lower than in nonsmoking group. 
The migration rate of each group was calculated. Each treatment group was used with 
PBMCs (FCS) supernatant, which were used in ELISAs. The data used in the three graphs 
above is the same. In order to avoid the all the significant difference markers being put 
together (it is not easy to interpret), the markers are separated in the three graphs (A, B, 
C). A showed that the positive control group (without IL-4) had lower migration rate than 
A B 
C 
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negative control group (with IL-4). B exhibited that all the nonsmoking inactivated 
bacteria stimulated groups had significantly higher migration rate than positive control 
group. C demonstrated that migration rates in nonsmoking inactivated bacteria 
stimulated groups were higher than smoking inactivated bacteria stimulated groups 
especially the comparing P. a. subgroups. The PBMCs supernatant stimulated by four 
types of inactivated bacteria (S. a., S. e., P. a., and E. f.) from smokers and nonsmokers. 
The incubation time for migration is 24 h. Each point represents the mean ± SEM error 
bars of control group inactivated bacteria treated groups from 7 healthy nonsmoking and 
7 smoking donors in duplicate experiments. Differences were regarded as statistically 
significant at values of *P < 0.05; ***P < 0.0005 in one-way ANOVA (nonparametric) 
multiple comparisons. 
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4. Discussion 
This pilot project aims to study the effects of smoking on inflammatory factors, in 
particularly the effects of IL-4 on wound healing. Due to the limited size of the study 
population, there was no attempt to balance other factors, such as gender and smoking 
status among the groups. The levels of various cytokines secreted by PBMCs have been 
used to estimate the true immune inflammatory response of the entire body, as this is also 
the method used in population biomonitoring studies (Le Meur et al., 1999, Arimilli et 
al., 2017, Prevost et al., 1990). In our ELISA experiments, we found that smokers show 
increased anti-inflammatory cytokines that have immunosuppressive effects. When 
stimulated by inactivated bacteria, PBMCs from smokers produce more both anti-
inflammatory cytokines and pro-inflammatory cytokines. The experimental model about 
the influence of IL-4 on the HaCaT cell migration has been used to simulate the epidermal 
wound healing. In our HaCaT cell migration study, the migration of each group treated 
with different levels of IL-4 was measured. In general, IL-4 inhibited HaCaT cell 
migration, subsequently delaying wound healing. Smoking causes delayed wound healing 
(Czernin and Waldherr, 2003, Pitts et al., 1999), which can be explained by increased 
basal IL-4 levels in smokers.   
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4.1. Smoking increased anti-inflammatory cytokines. 
First of all, it was detected by cytokine arrays that basal IL-4 and IL-10 was higher in the 
supernatant from PBMCs of smokers than those in supernatant from PBMCs of 
nonsmokers. This phenomenon is consistent with the conclusion that smoking could 
promote the production of more Th2 cytokines while suppressing the Th1 cytokines (de 
Heens et al., 2009, Lee et al., 2012). IL-4 can induce the differentiation of Th0 cells to 
Th2 cells that will produce more IL-4, which is a positive feedback (Robays et al., 2009). 
As a key regulator in acquired immunity, IL-4 has the effect of stimulating the 
propagation of activated T cells, up-regulating production of major histocompatibility 
complex II (MHC II) and inducing proliferation of B cells that produce IgE, whereas 
reducing Th1 cells, macrophages (Hershey et al., 1997). 
IL-10 that has multiple pleiotropic effects on inflammation and immune regulation is 
considered as an anti-inflammatory cytokine and is also known as cytokine synthesis 
inhibitory factor (CSIF) (Saxena et al., 2015). Although enhancing the antibody 
production, proliferation, maturation and survival of B cells, IL-10 down-regulates the 
MHC II antigens and expression of Th1 cytokines and stimulatory molecules on 
macrophages (Couper et al., 2008). IL-10 is able to repress the synthesis of pro-
inflammatory cytokines, such as IL-1β, TNFα, IFN-γ, IL-2, IL-6 and GM-CSF, produced 
by Th1 T cells or macrophages (Opp et al., 1995, Aste-Amezaga et al., 1998, Varma et 
al., 2001). Furthermore, it also exhibits a potent capability to inhibit dendritic or other 
antigen presenting cells (de Waal Malefyt et al., 1991, Mittal and Roche, 2015).  
IL-12, which is known as T cell stimulating factor, is a kind of anti-inflammatory cytokine 
(Hamza et al., 2010) and is mainly produced by activated antigen presenting cells, such 
as macrophages, dendritic cells, monocytes and B cells (Opstad et al., 2017). It could 
induce the differentiation of Th0 cells into Th1 cells and activate the growth of T cells. 
Moreover, it promotes the T cells and NK cells to produce TNF-α and IFN-γ, and 
counteracts the suppression effect of IL-4 on production of IFN-γ. IL-12 intermediates 
the proliferation of CD8+ CTL and elevated cytotoxic activity of NK cells. IL-12 secretion 
arises early in the innate and adaptive immune responses and appears to play a pivotal 
role in regulation of immunity and mediation of anti-tumor activity (Opstad et al., 2017). 
Low levels of IL-12 observed in smokers might have clinical implications regarding 
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inflammation and malignancy, which may partly explain why smokers are prone to 
COPD and lung cancer (Opstad et al., 2017). It was reported by Lee et al. that cigarette 
smoking reduced the secretion of IL-12, which is a Th1 cytokine (Lee et al., 2012). 
4.2. Smoking decreased the pro-inflammatory cytokines 
It was reported by Lee et al. that smoking reduced the Th1 cytokines (Lee et al., 2012). 
Th1 cells could produce IFN-γ, whereas Th2 cells could produce IL-4, IL-6, and IL-10. 
However, Barbieri et al. referred to higher levels of IL-1β and of TNF-α in smokers 
(Barbieri et al., 2011). As for the results in our study, without the inactivated bacteria 
stimulation, the basal pro-inflammatory cytokines levels seem to have no significant 
difference between smokers and nonsmokers. However, the increase of pro-inflammatory 
cytokines in non-smokers is more obvious than that in smokers, when stimulated with 
inactivated bacteria, for the reaction of PBMCs to bacteria was reduced by smoking. 
IL-1β (which is known as leukocytic pyrogen, lymphocyte activating factor, mononuclear 
cell factor or leukocytic endogenous mediator) (Bensi et al., 1987) is a member of the IL-
1 super family of cytokines (Lopez-Castejon and Brough, 2011, Striz, 2017). Ouyang et 
al. has reported that smoking suppressed the production of IL-1β in PBMCs (Ouyang et 
al., 2000). However, Moeintaghavi et al. reported that the IL-1β level was increased by 
smoking alone without other stimulating factors (Moeintaghavi et al., 2017). This was 
consistent with the result in our own IL-1β ELISA experiment, although the elevated IL-
1β didn’t increased much in the smokers compared to the nonsmokers. However, when 
stimulated with inactivated bacteria, the PBMCs from nonsmokers produced significantly 
much more IL-1β over the baseline, while the PBMCs from smokers didn’t produce as 
much IL-1β. We concluded that smoking weakened the response of PBMCs to TLR-
stimuli, which was supported by the result that TLR-stimulated inflammatory responses 
linked to the production of pro-inflammatory cytokines production were suppressed 
significantly by the combustible tobacco (Arimilli et al., 2017). TLR2/4 induced IL-1R-
associated kinase-1 (IRAK-1), phosphorylated p38 and activated NF-κB was inhibited in 
smokers, while levels of TLR4 protein expression and TLR2, MD-2 mRNA and CD14 
were not changed. The results indicate that the expression and activity of signaling 
intermediates were altered at the post-receptor level in relation to the immunosuppression 
caused by smoking (Chen et al., 2007). 
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TNF-α, that is also known as cachexia is one of the cytokines that initiates the acute phase 
response and also a cellular signaling cytokine involved in systemic inflammation. 
Although it can be produced by many cells such as NK cells, CD4+ T cells, mast cells 
and neutrophils, it is mainly produced by activated macrophages (Olszewski et al., 2007). 
Substantial amounts of TNF-α are secreted in response to LPS, or other microbial 
products, and IL-1. In our TNF-α ELISA experiment, it was shown that smoking alone 
could stimulate PBMCs to release slightly more TNF-α, that is in agreement with data by 
Boström et al. (Boström et al., 1998). However, Ouyang et al. have reported that 
production of TNF-α by PBMCs was reduced in smokers (Ouyang et al., 2000). 
Nevertheless, there is no doubt that LPS or inactivated bacteria could stimulated PBMCs 
to secrete more TNF-α via TLR (Lin and Yeh, 2005, Cezário et al., 2011). The increased 
amount in nonsmokers was higher than in smokers, which could probably be explained 
by smoking having the ability to impaire the reaction of PBMCs to the TLR-stimuli 
(Sopori and Kozak, 1998). 
IFN-γ, (also called type II interferon), which is predominantly produced by Th1 cells and 
NK cells, is essential for congenital and adaptive inmune responses against microbial 
infections. IFN-γ induces the macrophages to activate and could also promote the 
expression of MHC II molecules. Abnormal level of IFN-γ is linked to a variety of 
autoimmune diseases. It was believed that CD4+ Th1 lymphocytes, CD8+CTL, and NK 
cells predominantly produced IFN-γ (Schroder et al., 2004). Ouyang et al. reported that 
IFN-γ production was suppressed by smoking, whereas the basal IFN-γ level between 
smoking group and nonsmoking group didn’t have much difference in our ELISA. LPS, 
which is the most abundant component within the cell wall of Gram-negative bacteria 
(Ngkelo et al., 2012), could stimulate PBMCs to release IFN-γ (Negishi et al., 2011). 
However, the response of releasing more IFN-γ which was made by PBMCs to 
inactivated bacteria in our study was, however, not obvious. This discrepancy may be due 
to our insufficient sample size. It is also possible that IFN-γ, which is a Th1 cytokine 
(Sopori and Kozak, 1998) could be inhibited by smoking (Ouyang et al., 2000). Besides, 
IFN-γ is also a pro-inflammatory factor (Poyraz et al., 2013) that could be induced by 
other cytokines such as IL-12 and IL-18 (Kannan et al., 2011). Perhaps it was the 
combined effect of these two factors that led to the change of IFN-γ being inconspicuous 
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in our study. As for this phenomenon that the IFN-γ production cannot be increased 
clearly by inactivated bacteria in our experiments, is probably due to smoking that is 
associated with the negative regulation effect on Th1 cytokines.  
IL-6 is a pro-inflammatory cytokine that could be induced by LPS, TNF-α and IL-1 and 
serves as an indicator for systematized activation of proinflammatory cytokines (Frost et 
al., 2003). However, IL-6 also has a anti-inflammatory property which downregulates the 
synthesis of proinflammatory cytokines such as TNF-α, IL-1, IFN-γ, MIP-2 and GM-CSF, 
whereas the effect of IL-6 on attenuating the synthesis of anti-inflammatory cytokines 
such as IL-10 and transforming growth factor-β (TGF-β) is faint (Xing et al., 1998). IL-
6 is associated with generation of neutrophils in central blood and the production of the 
C-reactive protein (CRP) (Benedict et al., 2009). It induces the development of B cells 
and is antergic to the regulatory T cells (Srirangan and Choy, 2010). It was reported by 
Soliman et al. that smoking reduced the production of IL-6 (Soliman and Twigg, 1992). 
Within our ELISA experiments, the IL-6 was slightly decreased in smokers in the absence 
of stimulating inactivated bacteria, which was consistent in Soliman’s conclusion. 
However, Koo and Han reported that smoking alone had stimulated bronchial epithelial 
cells to produce IL-6 (Koo and Han, 2016). IL-6 is mainly released by macrophages in 
reaction to specific bacterial molecules, which are known as PAMPs. Nevertheless, in our 
study, with the existence of inactivated bacteria, the response of PBMCs to release more 
IL-6 was not obvious. In the reasearch advocated by Arimilli et al., TLR-stimulated LPS 
increased the production of IL-6, which was significantly decreased by smoking (Arimilli 
et al., 2017). This discrepancy could probably be associated with our insubstantial sample 
size since we performed a pilot study.  
4.3. Implication of IL-4 in wound healing.  
Wound healing is an crucial physiological procedure to sustain the completeness of the 
skin in animals or humans after trauma. It contains a complicated process that includes 
three successive yet overlapping stages: hemostasis and inflammation stage, propagation 
stage, and remolding stage (Wang et al., 2017). After skin damage the uncovered sub-
endothelium, collagen and tissue factors will trigger platelet gathering, that induces 
degranulation and discharging chemokines and growth factors (GFs) to construct a clot, 
and all the aforementioned processes will contribute successfull hemostasis (Gauglitz et 
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al., 2011). Neutrophils, the first inflammatory cells to come to the location of the wound, 
purge bacteria or debris to supply a friendly milieu for wound healing (Wang et al., 2017). 
Next, macrophages aggregate and promote the phagocytosis of bacteria (Berman et al., 
2017). The hemostasis and inflammatory stage often lasts 72 h. The subsequent 
propagation stage features an agggregation of substantial cells and aplenty conjunctional 
tissue. The wound encloses the keratinocytes, endothelial cells and fibroblasts. 
Extracellular matrix (ECM), which contains collagen, elastin, hyaluronic acid and 
proteoglycans, constructs a granulation tissue to substitute for the primarily formed clot 
(Su et al., 2010). Various cytokines are involved during wound healing, including the 
interleukin family (such as IL-4, IL-6), TGF family (such as TGF-β, which includes TGF-
β1, TGF-β2, and TGF-β3), and angiogenic factors (such as vascular epidermal growth 
factor [VEGF]). This second stage takes place from days to weeks (Su et al., 2010). Any 
abnormality during this process may lead to delayed wound healing. The final procedure 
is the remodelling stage, which requires an accurate equivalence between generation of 
new cells and apoptosis of old cells (Wang et al., 2017). Progressive degeneration of 
profusive ECM and development of type I collagen and the premature type III collagen 
are essential in this stage, which endures from a few months to years (Plikus et al., 2017, 
Tsai et al., 2018).    
The focus of our project was mainly on the second phase, within which many cytokines 
have critical effects. Among these cytokines, IL-4 is reported contradictorily about 
whether it promotes the wound healing. For example, in the study advocated by Salmon-
Ehr et al., local administration of IL-4 on deliberate wounds in rats significantly speeded 
up the healing, whereas an IL-4 antagonist significantly delayed the healing (Salmon-Ehr 
et al., 2000). However, Serezani et al. reported that IL-4 could induce delayed re-
epithelialization changes, and impair the response of keratinocyte to the wound by 
repression of fibronectin (Serezani et al., 2017). Thereby, we choose IL-4 as our research 
target and investigated the role of IL-4 in the activaty of keratinocytes. Actually, IL-4 
was found to have a suppressive effect on HaCaT cells migration. The migration rate in 
the HaCaT cells groups that were stimulated with the nonsmokers’ PBMCs supernatant 
was found to be higher than in the groups that were stimulated with smokers’ PBMCs 
supernatant. It corresponded to the results of cytokine array and ELISA that IL-4 level 
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was higher in smokers compared to nonsmokers. Combining the above conclusions, we 
can infer that elevated IL-4 could probably be the one of important factors underlying the 
mechanism whereby smoking leads to delayed wound healing. Th2 cytokines, such as IL-
4 and IL-13, were reported to downregulate the expression of genes encoding the 
structures of epidermal cells and their barrier function at the final phase of keratinocyte 
differentiation (Omori-Miyake et al., 2014). At the early phase of keratinocyte 
differentiation, IL-4 attenuates the expression levels of keratin, desmocollins, and 
desmogleins through the IL-4 receptor and STAT6 signalling pathway (Omori-Miyake et 
al., 2014). The p44/42 MAPK-dependent mechanism is a prerequisite for the IL-4-
induced reduction of expression of keratin (Omori-Miyake et al., 2014). Besides, the 
diminished mRNA expression level of desmogleins and desmocollins in keratinocytes 
stimulated by IL-4 may be the consequence of a reduction in keratin (Wallace et al., 2012).  
4.4. Limitation  
Admittedly, the sample size used in our pilot study is not very large, for ELISA and the 
cytokine array. Furthermore, because the blood we used was collected from each person 
on the spot, not taken from the blood bank, the concentration of PBMCs in our study was 
less than that in previous researches (Ouyang et al., 2000). As a matter of fact, we have 
only investigated seven kinds of cytokines. We firstly planned to perform cytokine arrays 
to have a general idea about the situation of 74 different cytokines between smokers and 
nonsmokers. Then, we used ELISAs to specifically detect several cytokines of interest. 
Besides, the method of investigating the influence of smoking on PBMCs in our research 
was taking blood from smokers and nonsmokers. Although the smoking PBMCs taken 
from our smokers directly could truly reflect the PBMCs in smokers, the age, gender, 
smoking history and intake of donors might have influenced our results. In our migration 
assay experiment, we have connected smoking, IL-4 and wound healing. Even though the 
smoking-E. f. sub-group had the highest level of IL-4 production, however, the migration 
rate in this sub-group was not, as expected, attenuated. IL-4 contained in the supernatant 
of the PBMCs was not comprehensively negatively related to the migration rate. The 
reason may be because many other factors, such as growth factor and ROS, (Avezov et 
al., 2014) are involved in the supernatant of the PBMCs. Thus, some factors contained in 
the PBMCs supernatant also had an effect on the mobility of HaCaT cells. The complexity 
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regarding the comprehensive function of the multiple factors in wound healing, together 
with the single factor effect we probed, made our present experiment count as pilot study. 
In the light of the mechanism of the process of smoking affecting the inflammatory 
responses and immunity, the signalling pathways through which the smoking changes the 
mRNA expression of various cytokines needs to be further investigated. Seeing that our 
in vitro HaCaT cells migration assay couldn’t adequately simulate and reproduce 
pathological changes in wound healing in vivo, the following schedules may include the 
establishment of animal models.  
 
4.5. Conclusion  
In this pilot project we aimed to clarify several questions as how cytokines were changed 
in smokers compared to nonsmoker. In addition, we had investigated how would smoking 
alter anti-inflammatory and pro-inflammatory cytokines, and how this alteration would 
be affected when the inactivated bacteria were present. Furthermore, we also determined 
whether IL-4 promotes or inhibits wound healing, and whether increased IL-4 in smokers 
contributed the delayed wound healing. In our research, it was PBMCs that mainly 
generated the cytokines. It was verified through cytokine arrays that smoking actually 
altered many of the 74 kinds of cytokines secreted by PBMCs stimulated by four types 
of inactivated bacteria. Above all, our cytokine arrays showed that IL-4 and IL-10 both 
of which are immune-regulatory cytokines was higher in smokers than in nonsmokers. 
As cytokines could be divided into pro-inflammatory cytokines (e.g., TNF-α, IFN-γ, IL-
6, and IL-1β) and immune-regulatory cytokines (e.g., IL-4, IL-10, and IL-12), ELISA 
was to be performed to specifically investigate the abovementioned seven cytokines. 
Without inactivated bacteria stimulation, smoking could downregulate the pro-
inflammatory cytokines and upregulate the immune-regulatory cytokines. Inactivated 
bacteria (S. a., S. e., P. a., and E. f.) could stimulate PBMCs to produce more cytokines 
with elevations in both pro-inflammatory cytokines and immune-regulatory cytokines. 
However, smoking could repress the ability of PBMCs to react to inactivated bacteria to 
increase the expression of cytokines (both immune-regulatory cytokines and pro-
inflammatory cytokines). IL-4, which was increased in the smokers’ PBMCs supernatant 
as well as inactivated bacteria, was found to inhibit the migration of HaCaT cells. We 
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could speculate that IL-4 plays an important role in the mechanism underlying smoking-
induced delayed wound healing. After all, our research just acts as a window for 
understanding the relationship among smoking, immunity and wound healing. In the 
following steps, the signaling pathway by which smoking induces the alteration of 
cytokines along with how IL-4 affects wound healing needs to be inquired. The animal 
models need to be established to investigate the in vivo wound healing mechanism, which 
could be transferred to patients. Certainly, several methods or materials are required to 
be updated or improved to design a guide to clinical treatment and prevention while 
improving the quality of life of patients.
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5.1 Summary 
Infection and delayed wound healing are two common complications in the clinic, which 
are more likely to happen due to smoking. Inflammation plays a key role in natural tissue 
repair, as well as being elemental to the host’s defense against microbial infection. 
Smoking induces inflammation and changes the congenital and acquired immune 
responses, which contributes to the increased occurrence of infection and poor wound 
healing. Therefore, comprehensive understanding of how smoking influences immunity 
along with wound healing is clinically essential for prevention and treatment. The purpose 
of our study is to inquire as to the mechanism by which smoking affects immunity and 
wound repair. Blood was taken from healthy non-smoking and smoking donors, and the 
PBMCs were isolated. The supernatant which was used as samples in ELISA, cytokine 
array and migration assay, was acquired after the PBMCs were first isolated and then 
incubated with four types of inactivated bacteria (Staphylococcus aureus, Staphylococcus 
epidermidis, Pseudomonas aeruginosa, Enterococcus faecalis) for 24 h. The cytokine 
array showed that the levels of IL-4 and IL-10 were higher in the supernatant from 
smokers’ PBMCs than those in the supernatant from non-smokers’ PBMCs. Nonsmoking 
PBMCs with inactivated bacteria exposure produced significantly higher cytokines (e.g., 
IL-1β and TNF-α) than nonsmoking PBMCs without inactivated bacteria exposure. 
Whereas, smoking PBMCs with inactivated bacteria exposure didn’t exhibit this trend. 
As for the migration assay, the migration rate of the positive control group (with IL-4) 
was lowest among all the groups, and the migration rate in inactivated bacteria stimulated 
groups of smokers was lower than that of non-smokers. In conclusion, smoking alone 
seems to downregulate the pro-inflammatory cytokine response and upregulate the anti-
inflammatory cytokine response. Though, inactivated bacteria could increase various 
cytokines released by PBMCs both in non-smokers and smokers, however, smoking 
seems to repress the reaction ability of PBMCs to inactivated bacteria to increase the 
expression of cytokines (both anti-inflammatory cytokines and pro-inflammatory 
cytokines). Moreover, our data suggest that IL-4 repressed the migration of the HaCaT 
cells and may, thus, impairing wound healing. Multiple mechanisms that may be 
responsible for the relationship among smoking, immunity and wound healing needs to 
be further investigated to guide clinical treatment and prevention.  
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5.2. Zusammenfassung  
Es gilt als gesichert, dass Rauchen verschiedene destruktive Auswirkungen auf den 
menschlichen Körper hat. Infektionen und Wundheilungsstörungen sind zwei häufige 
klinische Komplikationen, die scheinbar durch das Rauchen begünstigt werden. 
Entzündungsprozesse spielen eine Schlüsselrolle in der physiologischen 
Gewebewiederherstellung. Des Weiteren sind sie elementar für die Immunabwehr 
gegenüber mikrobiellen Infektionen. Rauchen verändert diese Entzündungsprozesse und 
verändert somit die angeborenen und erworbenen Immunreaktion. Bei Rauchern treten 
erhöht Infektionen und Wundheilungsstörungen auf. Daher ist ein umfassendes 
Verständnis der Pathologie, wie das Rauchen das Immunsystem und die Wundheilung 
negativ beeinflusst, aus klinischer Sicht essentiell, um zukünftige Behandlungsstrategien 
zu definieren. Deshalb war das Ziel der vorliegenden Studie, zunächst Mechanismen 
mittels derer das Rauchen auf das Immunsystem und die Geweberegeneration Einfluss 
nimmt, zu untersuchen. Hierzu wurde Blut von ‚gesunden‘ Rauchern und Nichtrauchern 
entnommen und die PBMCs (=Peripheral blood mononuclear cells/ dt. mononukleäre 
Zellen des peripheren Blutes) isoliert und kultiviert. Diese PBMCs wurden dann mit 
hitzeinaktivierten typischen Krankenhauskeimen (Staphylococcus aureus, 
Staphylococcus epidermidis, Pseudomonas aeruginosa, Enterococcus faecalis) inkubiert. 
Anschließend wurde der Überstand mittels verschiedener ELISAs, Zytokin-Arrays und 
Migrationsarrays untersucht. Unsere Ergebnisse der Zytokin-Arrays zeigen eindeutig, 
dass PBMC-Kulturüberstande von Rauchern höhere Interleukin (IL)-4 und IL-10 Spiegel 
sezernieren, als die von Nichtrauchern. Nach Inkubation mit den vier inaktivierten 
Bakterienarten produzierten die PBMCs von Nichtrauchern darüber hinaus signifikant 
erhöhte Konzentrationen an IL-1β und Tumornekrosefaktor (TNF)-α als die der Raucher. 
PBMCs von Nichtrauchern die durch inaktivierte Bakterien stimuliert wurden, 
sezernierten deutlich höhere IL-1 β und TNF- α Spiegel als PBMCs von Nichtrauchern, 
die nicht von inaktivierten Bakterien stimuliert wurden. Allerdings produzierten PBMCs 
von Rauchern nicht signifikant mehr von diesen beiden Zytokinen, wenn sie von 
inaktivierten Bakterien stimuliert wurden, als PBMCs von Rauchern, die nicht von 
Bakterien stimuliert wurden. 
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Im Migrationsassay war die Migrationsrate der positiven Kontrollgruppe (mit IL-4) die 
niedrigste aller Gruppen und die Migrationsrate der durch inaktivierte Bakterien 
stimulierte Rauchergruppe niedriger als die der Nichtraucher. Schließlich kann Rauchen 
allein die proinflammatorischen Zytokine herunterregulieren und entzündungshemmende 
Zytokine aufheben. Obwohl inaktivierte Bakterien die Freisetzung von mehr Zytokinen 
von PBMCs sowohl bei Rauchern als auch bei Nichtrauchern fördern können, besteht die 
Reaktion von PBMCs auf inaktivierte Bakterien darin, den Ausdruck von Zytokinen 
(entzündungshemmende Zytokine und pro-inflammatorische Zytokine) zu erhöhen, 
Rauchen kann diese Reaktion hemmen. IL-4 kann die Migration von HaCaT-Zellen 
hemmen und die Wundheilung beeinträchtigen. Man sollte jedoch bedenken, dass es noch 
eine Vielzahl weiterer pathologischer Mechanismen gibt, die durch das Rauchen, wie die 
Immunität und die Geweberegeneration, beeinflussen. Diese müssen jedoch noch weiter 
identifiziert werden. 
  
Bibliography 
 75 
6. Bibliography 
AGUDELO HIGUITA, N. I. & HUYCKE, M. M. 2014. Enterococcal Disease, 
Epidemiology, and Implications for Treatment. In: GILMORE, M. S., CLEWELL, 
D. B., IKE, Y. & SHANKAR, N. (eds.) Enterococci: From Commensals to 
Leading Causes of Drug Resistant Infection. Boston: Massachusetts Eye and Ear 
Infirmary. 
AHLUWALIA, I. B., SMITH, T., ARRAZOLA, R. A., PALIPUDI, K. M., DE 
QUEVEDO, I. G., PRASAD, V. M., COMMAR, A., SCHOTTE, K., 
GARWOOD, P. D. & ARMOUR, B. S. 2018. Current Tobacco Smoking, Quit 
Attempts, and Knowledge About Smoking Risks Among Persons Aged≥ 15 
Years—Global Adult Tobacco Survey, 28 Countries, 2008–2016. Morbidity and 
Mortality Weekly Report, 67, 1072. 
AKIYAMA, H., KANZAKI, H., TADA, J. & ARATA, J. 1998. Coagulase-negative 
staphylococci isolated from various skin lesions. The Journal of dermatology, 25, 
563-568. 
AKMATOV, M. K., MEHRAJ, J., GATZEMEIER, A., STRÖMPL, J., WITTE, W., 
KRAUSE, G. & PESSLER, F. 2014. Serial home-based self-collection of anterior 
nasal swabs to detect Staphylococcus aureus carriage in a randomized population-
based study in Germany. International Journal of Infectious Diseases, 25, 4-10. 
ALBERG, A. J., BROCK, M. V. & SAMET, J. M. 2005. Epidemiology of lung cancer: 
looking to the future. J Clin Oncol, 23, 3175-85. 
ALHEDE, M., BJARNSHOLT, T., GIVSKOV, M. & ALHEDE, M. 2014. Pseudomonas 
aeruginosa biofilms: mechanisms of immune evasion. Adv Appl Microbiol, 86, 1-
40. 
ANDERSON, G. P. & BOZINOVSKI, S. 2003. Acquired somatic mutations in the 
molecular pathogenesis of COPD. Trends in pharmacological sciences, 24, 71-
76. 
ANOOPKUMAR-DUKIE, S., CAREY, J., CONERE, T., O'SULLIVAN, E., VAN PELT, 
F. & ALLSHIRE, A. 2005. Resazurin assay of radiation response in cultured cells. 
The British journal of radiology, 78, 945-947. 
Bibliography 
 76 
ARCAVI, L. & BENOWITZ, N. L. 2004. Cigarette smoking and infection. Archives of 
internal medicine, 164, 2206-2216. 
ARIMILLI, S., SCHMIDT, E., DAMRATOSKI, B. E. & PRASAD, G. 2017. Role of 
oxidative stress in the suppression of immune responses in peripheral blood 
mononuclear cells exposed to combustible tobacco product preparation. 
Inflammation, 40, 1622-1630. 
ASSOCIATION, A. L. 2013. Trends in COPD (chronic bronchitis and emphysema): 
morbidity and mortality. Epidemiology and Statistics Unit, Research and Health 
Education Division. 
ASTE-AMEZAGA, M., MA, X., SARTORI, A. & TRINCHIERI, G. 1998. Molecular 
mechanisms of the induction of IL-12 and its inhibition by IL-10. The Journal of 
Immunology, 160, 5936-5944. 
AVEZOV, K., REZNICK, A. Z. & AIZENBUD, D. 2014. Oxidative damage in 
keratinocytes exposed to cigarette smoke and aldehydes. Toxicology in Vitro, 28, 
485-491. 
BALDASSARRI, L., BERTUCCINI, L., CRETI, R., FILIPPINI, P., AMMENDOLIA, 
M. G., KOCH, S., HUEBNER, J. & OREFICI, G. 2005. Glycosaminoglycans 
mediate invasion and survival of Enterococcus faecalis into macrophages. The 
Journal of infectious diseases, 191, 1253-1262. 
BAO, L., ALEXANDER, J. B., ZHANG, H., SHEN, K. & CHAN, L. S. 2016. 
Interleukin-4 downregulation of involucrin expression in human epidermal 
keratinocytes involves Stat6 sequestration of the coactivator CREB-binding 
protein. Journal of Interferon & Cytokine Research, 36, 374-381. 
BARBIERI, S. S., ZACCHI, E., AMADIO, P., GIANELLINI, S., MUSSONI, L., 
WEKSLER, B. B. & TREMOLI, E. 2011. Cytokines present in smokers' serum 
interact with smoke components to enhance endothelial dysfunction. 
Cardiovascular research, 90, 475-483. 
BARCELO, B., PONS, J., FERRER, J., SAULEDA, J., FUSTER, A. & AGUSTI, A. 
2008. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+ 
CD25+ regulatory T-lymphocyte response to tobacco smoking. European 
Respiratory Journal, 31, 555-562. 
Bibliography 
 77 
BARON, J. A. 1984. Smoking and estrogen-related disease. American journal of 
epidemiology, 119, 9. 
BATES, M. N., KHALAKDINA, A., PAI, M., CHANG, L., LESSA, F. & SMITH, K. R. 
2007. Risk of tuberculosis from exposure to tobacco smoke: a systematic review 
and meta-analysis. Arch Intern Med, 167, 335-42. 
BAUER, C. M., DEWITTE-ORR, S. J., HORNBY, K. R., ZAVITZ, C. C., LICHTY, B. 
D., STÄMPFLI, M. R. & MOSSMAN, K. L. 2008. Cigarette smoke suppresses 
type I interferon-mediated antiviral immunity in lung fibroblast and epithelial 
cells. Journal of Interferon & Cytokine Research, 28, 167-179. 
BECKER, C. E. & O’NEILL, L. A. Inflammasomes in inflammatory disorders: the role 
of TLRs and their interactions with NLRs.  Seminars in immunopathology, 2007. 
Springer, 239-248. 
BENEDICT, C., SCHELLER, J. R., ROSE-JOHN, S., BORN, J. & MARSHALL, L. 
2009. Enhancing influence of intranasal interleukin-6 on slow-wave activity and 
memory consolidation during sleep. The FASEB Journal, 23, 3629-3636. 
BENOWITZ, N. L. 2003. Cigarette smoking and cardiovascular disease: 
pathophysiology and implications for treatment. Prog Cardiovasc Dis, 46, 91-111. 
BENSI, G., RAUGEI, G., PALLA, E., CARINCI, V., BUONAMASSA, D. T. & MELLI, 
M. 1987. Human interleukin-1 beta gene. Gene, 52, 95-101. 
BERGSTROM, J. 2004. Tobacco smoking and chronic destructive periodontal disease. 
Odontology, 92, 1-8. 
BERMAN, B., MADERAL, A. & RAPHAEL, B. 2017. Keloids and hypertrophic scars: 
pathophysiology, classification, and treatment. Dermatologic Surgery, 43, S3-S18. 
BOS, J. L. 1989. Ras oncogenes in human cancer: a review. Cancer research, 49, 4682-
4689. 
BOSTRÖM, L., LINDER, L. E. & BERGSTRÖM, J. 1998. Clinical expression of TNF-
α in smoking-associated periodontal disease. Journal of Clinical Periodontology, 
25, 767-773. 
BOUZIGON, E., CORDA, E., ASCHARD, H., DIZIER, M. H., BOLAND, A., 
BOUSQUET, J., CHATEIGNER, N., GORMAND, F., JUST, J., LE MOUAL, 
N., SCHEINMANN, P., SIROUX, V., VERVLOET, D., ZELENIKA, D., PIN, I., 
Bibliography 
 78 
KAUFFMANN, F., LATHROP, M. & DEMENAIS, F. 2008. Effect of 17q21 
variants and smoking exposure in early-onset asthma. N Engl J Med, 359, 1985-
94. 
BROWN, C. W., ORME, T. J. & RICHARDSON, H. D. 1986. The rate of pseudarthrosis 
(surgical nonunion) in patients who are smokers and patients who are nonsmokers: 
a comparison study. Spine, 11, 942-943. 
BURNS, A. R., HOSFORD, S. P., DUNN, L. A., WALKER, D. C. & HOGG, J. C. 1989. 
Respiratory epithelial permeability after cigarette smoke exposure in guinea pigs. 
Journal of Applied Physiology, 66, 2109-2116. 
CAPEWELL, S., HAYES, D. K., FORD, E. S., CRITCHLEY, J. A., CROFT, J. B., 
GREENLUND, K. J. & LABARTHE, D. R. 2009. Life-years gained among US 
adults from modern treatments and changes in the prevalence of 6 coronary heart 
disease risk factors between 1980 and 2000. American journal of epidemiology, 
170, 229-236. 
CARPENTER, M. C. T., DIETZ, M. J. W., LEUNG, K. Y., HANSCOM, D. A. & 
WAGNER, T. A. 1996. Repair of a Pseudarthrosis of the Lumbar Spine.: A 
Functional Outcome Study. JBJS, 78, 712-720. 
CAYCI, C., RUSSO, M., CHEEMA, F., MARTENS, T., OZCAN, V., ARGENZIANO, 
M., OZ, M. C. & ASCHERMAN, J. 2008. Risk analysis of deep sternal wound 
infections and their impact on long-term survival: a propensity analysis. Annals 
of plastic surgery, 61, 294-301. 
CEZÁRIO, G. A. G., OLIVEIRA, L. R. C. D., PERESI, E., NICOLETE, V. C., 
POLETTINI, J., LIMA, C. R. G. D., GATTO, M. & CALVI, S. A. 2011. Analysis 
of the expression of toll-like receptors 2 and 4 and cytokine production during 
experimental Leishmania chagasi infection. Memorias do Instituto Oswaldo Cruz, 
106, 573-583. 
CHALMERS, G. W., MACLEOD, K. J., THOMSON, L., LITTLE, S. A., MCSHARRY, 
C. & THOMSON, N. C. 2001. Smoking and airway inflammation in patients with 
mild asthma. Chest, 120, 1917-22. 
CHAUDHURI, R., LIVINGSTON, E., MCMAHON, A. D., THOMSON, L., 
BORLAND, W. & THOMSON, N. C. 2003. Cigarette smoking impairs the 
Bibliography 
 79 
therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit 
Care Med, 168, 1308-11. 
CHEN, H., COWAN, M. J., HASDAY, J. D., VOGEL, S. N. & MEDVEDEV, A. E. 2007. 
Tobacco smoking inhibits expression of proinflammatory cytokines and 
activation of IL-1R-associated kinase, p38, and NF-κB in alveolar macrophages 
stimulated with TLR2 and TLR4 agonists. The Journal of Immunology, 179, 
6097-6106. 
CHEN, Y.-L., GHAFAR, N. A., KARUNA, R., FU, Y., LIM, S. P., SCHUL, W., GU, F., 
HERVE, M., YOKOHAMA, F. & WANG, G. 2014. Activation of peripheral 
blood mononuclear cells by dengue virus infection depotentiates balapiravir. 
Journal of virology, 88, 1740-1747. 
CHOW, J., THAL, L., PERRI, M., VAZQUEZ, J. A., DONABEDIAN, S., CLEWELL, 
D. & ZERVOS, M. 1993. Plasmid-associated hemolysin and aggregation 
substance production contribute to virulence in experimental enterococcal 
endocarditis. Antimicrobial agents and chemotherapy, 37, 2474-2477. 
CHUNG, K. F. 2005. Inflammatory mediators in chronic obstructive pulmonary disease. 
Current Drug Targets-Inflammation & Allergy, 4, 619-625. 
CHURG, A., DAI, J., TAI, H., XIE, C. & WRIGHT, J. L. 2002. Tumor necrosis factor-α 
is central to acute cigarette smoke–induced inflammation and connective tissue 
breakdown. American journal of respiratory and critical care medicine, 166, 849-
854. 
CIGANA, C., CURCURU, L., LEONE, M. R., IERANO, T., LORE, N. I., BIANCONI, 
I., SILIPO, A., COZZOLINO, F., LANZETTA, R., MOLINARO, A., 
BERNARDINI, M. L. & BRAGONZI, A. 2009. Pseudomonas aeruginosa 
exploits lipid A and muropeptides modification as a strategy to lower innate 
immunity during cystic fibrosis lung infection. PLoS One, 4, e8439. 
CISZEK-LENDA, M., STRUS, M., WALCZEWSKA, M., MAJKA, G., MACHUL-
ZWIRBLA, A., MIKOLAJCZYK, D., GORSKA, S., GAMIAN, A., CHAIN, B. 
& MARCINKIEWICZ, J. 2019. Pseudomonas aeruginosa biofilm is a potent 
inducer of phagocyte hyperinflammation. Inflamm Res. 
Bibliography 
 80 
COEN, P. G., TULLY, J., STUART, J. M., ASHBY, D., VINER, R. M. & BOOY, R. 
2006. Is it exposure to cigarette smoke or to smokers which increases the risk of 
meningococcal disease in teenagers? International journal of epidemiology, 35, 
330-336. 
CONTROL, C. F. D. & PREVENTION 1993. Mortality trends for selected smoking-
related cancers and breast cancer--United States, 1950-1990. MMWR. Morbidity 
and mortality weekly report, 42, 857, 863. 
CORREA, P. C., BARRETO, S. M. & PASSOS, V. M. 2009. Smoking-attributable 
mortality and years of potential life lost in 16 Brazilian capitals, 2003: a 
prevalence-based study. BMC Public Health, 9, 206. 
CORRY, D. B., AMPEL, N. M., CHRISTIAN, L., LOCKSLEY, R. M. & GALGIANI, 
J. N. 1996. Cytokine production by peripheral blood mononuclear cells in human 
coccidioidomycosis. Journal of Infectious Diseases, 174, 440-443. 
COUPER, K. N., BLOUNT, D. G. & RILEY, E. M. 2008. IL-10: the master regulator of 
immunity to infection. The Journal of Immunology, 180, 5771-5777. 
CZERNIN, J. & WALDHERR, C. 2003. Cigarette smoking and coronary blood flow. 
Progress in cardiovascular diseases, 45, 395-404. 
DAVID, M. Z. & DAUM, R. S. 2010. Community-associated methicillin-resistant 
Staphylococcus aureus: epidemiology and clinical consequences of an emerging 
epidemic. Clinical microbiology reviews, 23, 616-687. 
DAVIS, R. M., WAKEFIELD, M., AMOS, A. & GUPTA, P. C. 2007. The Hitchhiker's 
Guide to Tobacco Control: a global assessment of harms, remedies, and 
controversies. Annu. Rev. Public Health, 28, 171-194. 
DE HEENS, G. T., VAN DER VELDEN, U. & LOOS, B. 2009. Cigarette smoking 
enhances T cell activation and a Th2 immune response; an aspect of the 
pathophysiology in periodontal disease. Cytokine, 47, 157-161. 
DE WAAL MALEFYT, R., ABRAMS, J., BENNETT, B., FIGDOR, C. G. & DE VRIES, 
J. E. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: 
an autoregulatory role of IL-10 produced by monocytes. Journal of Experimental 
Medicine, 174, 1209-1220. 
Bibliography 
 81 
DO, E. & MAES, H. 2016. Narrative review of genes, environment, and cigarettes. 
Annals of medicine, 48, 337-351. 
DONKOR, O., RAVIKUMAR, M., PROUDFOOT, O., DAY, S., APOSTOLOPOULOS, 
V., PAUKOVICS, G., VASILJEVIC, T., NUTT, S. & GILL, H. 2012. Cytokine 
profile and induction of T helper type 17 and regulatory T cells by human 
peripheral mononuclear cells after microbial exposure. Clinical & Experimental 
Immunology, 167, 282-295. 
DRANNIK, A. G., POULADI, M. A., ROBBINS, C. S., GONCHAROVA, S. I., 
KIANPOUR, S. & STÄMPFLI, M. R. 2004. Impact of cigarette smoke on 
clearance and inflammation after Pseudomonas aeruginosa infection. American 
journal of respiratory and critical care medicine, 170, 1164-1171. 
DYE, J. A. & ADLER, K. B. 1994. Effects of cigarette smoke on epithelial cells of the 
respiratory tract. Thorax, 49, 825. 
EDWARDS, R. 2004. The problem of tobacco smoking. Bmj, 328, 217-219. 
EGLESTON, B. L., MEIRELES, S. I., FLIEDER, D. B. & CLAPPER, M. L. Population-
based trends in lung cancer incidence in women.  Seminars in oncology, 2009. 
Elsevier, 506-515. 
EKPU, V. U. & BROWN, A. K. 2015. The economic impact of smoking and of reducing 
smoking prevalence: review of evidence. Tobacco use insights, 8, TUI. S15628. 
ELBE-BUÈRGER, A., OLT, S., STINGL, G., EGYED, A., KLUBAL, R., MANN, U., 
RAPPERSBERGER, K. & ROT, A. 2002. Overexpression of IL-4 alters the 
homeostasis in the skin. Journal of investigative dermatology, 118, 767-778. 
EMING, S. A., WYNN, T. A. & MARTIN, P. 2017. Inflammation and metabolism in 
tissue repair and regeneration. Science, 356, 1026-1030. 
FAGERSTRÖM, K. 2002. The epidemiology of smoking. Drugs, 62, 1-9. 
FEGHALI-BOSTWICK, C. A., GADGIL, A. S., OTTERBEIN, L. E., PILEWSKI, J. M., 
STONER, M. W., CSIZMADIA, E., ZHANG, Y., SCIURBA, F. C. & DUNCAN, 
S. R. 2008. Autoantibodies in patients with chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med, 177, 156-63. 
FEY, P. D. & OLSON, M. E. 2010. Current concepts in biofilm formation of 
Staphylococcus epidermidis. Future microbiology, 5, 917-933. 
Bibliography 
 82 
FLETCHER, C. & PETO, R. 1977. The natural history of chronic airflow obstruction. Br 
Med J, 1, 1645-8. 
FOWLES, J. & DYBING, E. 2003. Application of toxicological risk assessment 
principles to the chemical constituents of cigarette smoke. Tobacco control, 12, 
424-430. 
FRANCES, C., BOISNIC, S., HARTMANN, D., DAUTZENBERG, B., BRANCHET, 
M., CHARPENTIER, Y. L. & ROBERT, L. 1991. Changes in the elastic tissue 
of the non - sun - exposed skin of cigarette smokers. British Journal of 
Dermatology, 125, 43-47. 
FREEDMAN, N. D., SILVERMAN, D. T., HOLLENBECK, A. R., SCHATZKIN, A. & 
ABNET, C. C. 2011. Association between smoking and risk of bladder cancer 
among men and women. Jama, 306, 737-745. 
FRIBERG, D., BRYANT, J., SHANNON, W. & WHITESIDE, T. 1994. In vitro cytokine 
production by normal human peripheral blood mononuclear cells as a measure of 
immunocompetence or the state of activation. Clin. Diagn. Lab. Immunol., 1, 261-
268. 
FROST, R. A., NYSTROM, G. J. & LANG, C. H. 2003. Lipopolysaccharide and 
proinflammatory cytokines stimulate interleukin-6 expression in C2C12 
myoblasts: role of the Jun NH2-terminal kinase. American Journal of Physiology-
Regulatory, Integrative and Comparative Physiology, 285, R1153-R1164. 
FUSS, I. J., KANOF, M. E., SMITH, P. D. & ZOLA, H. 2009. Isolation of whole 
mononuclear cells from peripheral blood and cord blood. Current protocols in 
immunology, 85, 7.1. 1-7.1. 8. 
GABBIANI, G. 2003. The myofibroblast in wound healing and fibrocontractive diseases. 
The Journal of Pathology: A Journal of the Pathological Society of Great Britain 
and Ireland, 200, 500-503. 
GALANTI, L. M. 2008. Tobacco smoking cessation management: integrating varenicline 
in current practice. Vascular health and risk management, 4, 837. 
GASCHLER, G. J., SKRTIC, M., ZAVITZ, C. C., LINDAHL, M., ONNERVIK, P.-O., 
MURPHY, T. F., SETHI, S. & STÄMPFLI, M. R. 2009. Bacteria challenge in 
Bibliography 
 83 
smoke-exposed mice exacerbates inflammation and skews the inflammatory 
profile. American journal of respiratory and critical care medicine, 179, 666-675. 
GASCHLER, G. J., ZAVITZ, C. C., BAUER, C. M., SKRTIC, M., LINDAHL, M., 
ROBBINS, C. S., CHEN, B. & STAMPFLI, M. R. 2008. Cigarette smoke 
exposure attenuates cytokine production by mouse alveolar macrophages. 
American journal of respiratory cell and molecular biology, 38, 218-226. 
GASTON, M. & SIMPSON, A. 2007. Inhibition of fracture healing. The Journal of bone 
and joint surgery. British volume, 89, 1553-1560. 
GAUGLITZ, G. G., KORTING, H. C., PAVICIC, T., RUZICKA, T. & JESCHKE, M. 
G. 2011. Hypertrophic scarring and keloids: pathomechanisms and current and 
emerging treatment strategies. Molecular medicine, 17, 113. 
GENERAL, S. 2001. Health consequences of tobacco use among women, reproductive 
outcomes. Women and smoking. Rockville, MD, US Department of Health and 
Human Services, 272-307. 
GILMORE, M. S., CLEWELL, D. B., IKE, Y. & SHANKAR, N. 2014. Enterococci as 
Indicators of Environmental Fecal Contamination--Enterococci: From 
Commensals to Leading Causes of Drug Resistant Infection. 
GJØDSBØL, K., CHRISTENSEN, J. J., KARLSMARK, T., JØRGENSEN, B., KLEIN, 
B. M. & KROGFELT, K. A. 2006. Multiple bacterial species reside in chronic 
wounds: a longitudinal study. International wound journal, 3, 225-231. 
GRUMELLI, S., CORRY, D. B., SONG, L. Z., SONG, L., GREEN, L., HUH, J., 
HACKEN, J., ESPADA, R., BAG, R., LEWIS, D. E. & KHERADMAND, F. 
2004. An immune basis for lung parenchymal destruction in chronic obstructive 
pulmonary disease and emphysema. PLoS Med, 1, e8. 
GUALANO, R. C., HANSEN, M. J., VLAHOS, R., JONES, J. E., PARK-JONES, R. A., 
DELIYANNIS, G., TURNER, S. J., DUCA, K. A. & ANDERSON, G. P. 2008. 
Cigarette smoke worsens lung inflammation and impairs resolution of influenza 
infection in mice. Respiratory research, 9, 53. 
HAMZA, T., BARNETT, J. B. & LI, B. 2010. Interleukin 12 a key immunoregulatory 
cytokine in infection applications. International journal of molecular sciences, 11, 
789-806. 
Bibliography 
 84 
HARADA, M., HIROTA, T., JODO, A. I., DOI, S., KAMEDA, M., FUJITA, K., 
MIYATAKE, A., ENOMOTO, T., NOGUCHI, E. & YOSHIHARA, S. 2009. 
Functional analysis of the thymic stromal lymphopoietin variants in human 
bronchial epithelial cells. American journal of respiratory cell and molecular 
biology, 40, 368-374. 
HARRISON, O. J., FOLEY, J., BOLOGNESE, B. J., LONG III, E., PODOLIN, P. L. & 
WALSH, P. T. 2008. Airway infiltration of CD4+ CCR6+ Th17 type cells 
associated with chronic cigarette smoke induced airspace enlargement. 
Immunology letters, 121, 13-21. 
HATSUKAMI, D. K., STEAD, L. F. & GUPTA, P. C. 2008. Tobacco addiction. The 
Lancet, 371, 2027-2038. 
HEALTH, U. D. O. & SERVICES, H. 2004. The health consequences of smoking: a 
report of the Surgeon General. US Department of Health and Human Services, 
Centers for Disease Control and …. 
HEALTH, U. D. O. & SERVICES, H. 2014. The health consequences of smoking—50 
years of progress: a report of the Surgeon General. Atlanta, GA: US Department 
of Health and Human Services, Centers for Disease …. 
HELIÖVAARA, M., AHO, K., AROMAA, A., KNEKT, P. & REUNANEN, A. 1993. 
Smoking and risk of rheumatoid arthritis. The Journal of rheumatology, 20, 1830-
1835. 
HERR, C., BEISSWENGER, C., HESS, C., KANDLER, K., SUTTORP, N., WELTE, 
T., SCHRÖDER, J.-M., VOGELMEIER, C. & GROUP, R. B. F. T. C. S. 2009. 
Suppression of pulmonary innate host defence in smokers. Thorax, 64, 144-149. 
HERSHEY, G. K. K., FRIEDRICH, M. F., ESSWEIN, L. A., THOMAS, M. L. & 
CHATILA, T. A. 1997. The association of atopy with a gain-of-function mutation 
in the α subunit of the interleukin-4 receptor. New England Journal of Medicine, 
337, 1720-1725. 
HIDRON, A. I., EDWARDS, J. R., PATEL, J., HORAN, T. C., SIEVERT, D. M., 
POLLOCK, D. A. & FRIDKIN, S. K. 2008. Antimicrobial-resistant pathogens 
associated with healthcare-associated infections: annual summary of data reported 
to the National Healthcare Safety Network at the Centers for Disease Control and 
Bibliography 
 85 
Prevention, 2006–2007. Infection Control & Hospital Epidemiology, 29, 996-
1011. 
HIRSCHFELD, J. 2014. Dynamic interactions of neutrophils and biofilms. J Oral 
Microbiol, 6, 26102. 
HIRT, H., SCHLIEVERT, P. M. & DUNNY, G. M. 2002. In vivo induction of virulence 
and antibiotic resistance transfer in Enterococcus faecalis mediated by the sex 
pheromone-sensing system of pCF10. Infection and immunity, 70, 716-723. 
HODGE, S., HODGE, G., AHERN, J., JERSMANN, H., HOLMES, M. & REYNOLDS, 
P. N. 2007. Smoking alters alveolar macrophage recognition and phagocytic 
ability: implications in chronic obstructive pulmonary disease. American journal 
of respiratory cell and molecular biology, 37, 748-755. 
HUANG MF, L. W., MA YC 2005. A study of reactive oxygen species in mainstream of 
cigarette. Indoor Air, 15, 135-140. 
HUTTUNEN, R., HEIKKINEN, T. & SYRJANEN, J. 2011. Smoking and the outcome 
of infection. J Intern Med, 269, 258-69. 
HUXLEY, R. R. & WOODWARD, M. 2011. Cigarette smoking as a risk factor for 
coronary heart disease in women compared with men: a systematic review and 
meta-analysis of prospective cohort studies. The Lancet, 378, 1297-1305. 
ITO, K. & BARNES, P. J. 2009. COPD as a disease of accelerated lung aging. Chest, 
135, 173-180. 
JAHNSEN, F. L., STRICKLAND, D. H., THOMAS, J. A., TOBAGUS, I. T., NAPOLI, 
S., ZOSKY, G. R., TURNER, D. J., SLY, P. D., STUMBLES, P. A. & HOLT, P. 
G. 2006. Accelerated antigen sampling and transport by airway mucosal dendritic 
cells following inhalation of a bacterial stimulus. The Journal of Immunology, 177, 
5861-5867. 
JAMAL, A., HOMA, D. M., O’CONNOR, E., BABB, S. D., CARABALLO, R. S., 
SINGH, T., HU, S. S. & KING, B. A. 2015. Current cigarette smoking among 
adults—United States, 2005–2014. Morbidity and Mortality Weekly Report, 64, 
1233-1240. 
JAMROZIK, K. 2004. ABC of smoking cessation: The problem of tobacco smoking. 
British Medical Journal, 328, 1007-1009. 
Bibliography 
 86 
JEURINK, P. V., VISSERS, Y. M., RAPPARD, B. & SAVELKOUL, H. F. 2008. T cell 
responses in fresh and cryopreserved peripheral blood mononuclear cells: kinetics 
of cell viability, cellular subsets, proliferation, and cytokine production. 
Cryobiology, 57, 91-103. 
JHA, P., CHALOUPKA, F. J., MOORE, J., GAJALAKSHMI, V., GUPTA, P. C., PECK, 
R., ASMA, S. & ZATONSKI, W. 2006. Tobacco addiction. Disease Control 
Priorities in Developing Countries. 2nd edition. The International Bank for 
Reconstruction and Development/The World Bank. 
JHA, P., RAMASUNDARAHETTIGE, C., LANDSMAN, V., ROSTRON, B., THUN, 
M., ANDERSON, R. N., MCAFEE, T. & PETO, R. 2013. 21st-century hazards 
of smoking and benefits of cessation in the United States. New England Journal 
of Medicine, 368, 341-350. 
JI, H., HOUGHTON, A., MARIANI, T., PERERA, S., KIM, C., PADERA, R., TONON, 
G., MCNAMARA, K., MARCONCINI, L. & HEZEL, A. 2006. K-ras activation 
generates an inflammatory response in lung tumors. Oncogene, 25, 2105. 
JONES, L. L., HASHIM, A., MCKEEVER, T., COOK, D. G., BRITTON, J. & 
LEONARDI-BEE, J. 2011. Parental and household smoking and the increased 
risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: 
systematic review and meta-analysis. Respiratory research, 12, 5. 
JULIER, Z., PARK, A. J., BRIQUEZ, P. S. & MARTINO, M. M. 2017. Promoting tissue 
regeneration by modulating the immune system. Acta biomaterialia, 53, 13-28. 
JUNGHANS, V., JUNG, T. & NEUMANN, C. 1996. Human keratinocytes constitutively 
express IL-4 receptor molecules and respond to IL-4 with an increase in B7/BB1 
expression. Experimental dermatology, 5, 316-324. 
JUNIE, L., SIMON, L. & PANDREA, S. 2014. Resistance to the chemotherapeutic 
agents of Staphylococcus aureus strains isolated from hospitalized patients. 
International Journal of Infectious Diseases, 21, 79-80. 
JUST, M., MONSÓ, E., RIBERA, M., CARLES LORENZO, J., MORERA, J. & 
FERRANDIZ, C. 2005. Relationships between lung function, smoking and 
morphology of dermal elastic fibres. Experimental dermatology, 14, 744-751. 
Bibliography 
 87 
KALKHORAN, S., BENOWITZ, N. L. & RIGOTTI, N. A. 2018. Reprint of: Prevention 
and Treatment of Tobacco Use: JACC Health Promotion Series. Journal of the 
American College of Cardiology, 72, 2964-2979. 
KANG, M.-J., LEE, C. G., LEE, J.-Y., CRUZ, C. S. D., CHEN, Z. J., ENELOW, R. & 
ELIAS, J. A. 2008. Cigarette smoke selectively enhances viral PAMP–and virus-
induced pulmonary innate immune and remodeling responses in mice. The 
Journal of clinical investigation, 118, 2771-2784. 
KANNAN, Y., YU, J., RAICES, R. M., SESHADRI, S., WEI, M., CALIGIURI, M. A. 
& WEWERS, M. D. 2011. IκBζ augments IL-12–and IL-18–mediated IFN-γ 
production in human NK cells. Blood, 117, 2855-2863. 
KARK, J. D., LEBIUSH, M. & RANNON, L. 1982. Cigarette smoking as a risk factor 
for epidemic a (h1n1) influenza in young men. New England Journal of Medicine, 
307, 1042-1046. 
KATIAL, R. K., SACHANANDANI, D., PINNEY, C. & LIEBERMAN, M. M. 1998. 
Cytokine production in cell culture by peripheral blood mononuclear cells from 
immunocompetent hosts. Clin. Diagn. Lab. Immunol., 5, 78-81. 
KENFIELD, S. A., STAMPFER, M. J., ROSNER, B. A. & COLDITZ, G. A. 2008. 
Smoking and smoking cessation in relation to mortality in women. Jama, 299, 
2037-2047. 
KIM, H., LIU, X., KOBAYASHI, T., CONNER, H., KOHYAMA, T., WEN, F.-Q., 
FANG, Q., ABE, S., BITTERMAN, P. & RENNARD, S. I. 2004. Reversible 
cigarette smoke extract–induced DNA damage in human lung fibroblasts. 
American journal of respiratory cell and molecular biology, 31, 483-490. 
KIRKHAM, P. A., SPOONER, G., RAHMAN, I. & ROSSI, A. G. 2004. Macrophage 
phagocytosis of apoptotic neutrophils is compromised by matrix proteins 
modified by cigarette smoke and lipid peroxidation products. Biochemical and 
biophysical research communications, 318, 32-37. 
KOLAPPAN, C. & GOPI, P. 2002. Tobacco smoking and pulmonary tuberculosis. 
Thorax, 57, 964-966. 
Bibliography 
 88 
KOO, J. B. & HAN, J. S. 2016. Cigarette smoke extract-induced interleukin-6 expression 
is regulated by phospholipase D1 in human bronchial epithelial cells. J Toxicol 
Sci, 41, 77-89. 
KRAMER, N., WALZL, A., UNGER, C., ROSNER, M., KRUPITZA, G., 
HENGSTSCHLÄGER, M. & DOLZNIG, H. 2013. In vitro cell migration and 
invasion assays. Mutation Research/Reviews in Mutation Research, 752, 10-24. 
KROENING, P. R., BARNES, T. W., PEASE, L., LIMPER, A., KITA, H. & 
VASSALLO, R. 2008. Cigarette smoke-induced oxidative stress suppresses 
generation of dendritic cell IL-12 and IL-23 through ERK-dependent pathways. J 
Immunol, 181, 1536-47. 
LAAN, M., BOZINOVSKI, S. & ANDERSON, G. P. 2004. Cigarette smoke inhibits 
lipopolysaccharide-induced production of inflammatory cytokines by suppressing 
the activation of activator protein-1 in bronchial epithelial cells. The Journal of 
Immunology, 173, 4164-4170. 
LE MEUR, Y., LORGEOT, V., ALDIGIER, J.-C., WIJDENES, J., LEROUX-ROBERT, 
C. & PRALORAN, V. 1999. Whole blood production of monocytic cytokines 
(IL-1 β, IL-6, TNF-α, sIL-6R, IL-1Ra) in haemodialysed patients. Nephrology 
Dialysis Transplantation, 14, 2420-2426. 
LEBRETON, F., WILLEMS, R. J. & GILMORE, M. S. 2014. Enterococcus diversity, 
origins in nature, and gut colonization. Enterococci: from commensals to leading 
causes of drug resistant infection [Internet]. Massachusetts Eye and Ear Infirmary. 
LEE, J., TANEJA, V. & VASSALLO, R. 2012. Cigarette smoking and inflammation: 
cellular and molecular mechanisms. Journal of dental research, 91, 142-149. 
LEE, S. H., GOSWAMI, S., GRUDO, A., SONG, L. Z., BANDI, V., GOODNIGHT-
WHITE, S., GREEN, L., HACKEN-BITAR, J., HUH, J., BAKAEEN, F., 
COXSON, H. O., COGSWELL, S., STORNESS-BLISS, C., CORRY, D. B. & 
KHERADMAND, F. 2007. Antielastin autoimmunity in tobacco smoking-
induced emphysema. Nat Med, 13, 567-9. 
LEVINSON, W. 2008. Review of medical microbiology and immunology, The McGraw-
Hill Companies. 
Bibliography 
 89 
LIN, W.-J. & YEH, W.-C. 2005. Implication of Toll-like receptor and tumor necrosis 
factor α signaling in septic shock. Shock, 24, 206-209. 
LIU, G., WANG, J., PARK, Y.-J., TSURUTA, Y., LORNE, E. F., ZHAO, X. & 
ABRAHAM, E. 2008. High mobility group protein-1 inhibits phagocytosis of 
apoptotic neutrophils through binding to phosphatidylserine. The Journal of 
Immunology, 181, 4240-4246. 
LOPEZ-CASTEJON, G. & BROUGH, D. 2011. Understanding the mechanism of IL-1β 
secretion. Cytokine & growth factor reviews, 22, 189-195. 
LORE, N. I., CIGANA, C., DE FINO, I., RIVA, C., JUHAS, M., SCHWAGER, S., 
EBERL, L. & BRAGONZI, A. 2012. Cystic fibrosis-niche adaptation of 
Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLoS One, 
7, e35648. 
LOSSOUARN, J., BRIET, A., MONCAUT, E., FURLAN, S., BOUTEAU, A., SON, O., 
LEROY, M., DUBOW, M. S., LECOINTE, F. & SERROR, P. 2019. 
Enterococcus faecalis Countermeasures Defeat a Virulent Picovirinae 
Bacteriophage. Viruses, 11, 48. 
LU, L.-F., LIND, E. F., GONDEK, D. C., BENNETT, K. A., GLEESON, M. W., PINO-
LAGOS, K., SCOTT, Z. A., COYLE, A. J., REED, J. L. & VAN SNICK, J. 2006. 
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature, 442, 
997. 
LU, L.-M., ZAVITZ, C. C., CHEN, B., KIANPOUR, S., WAN, Y. & STÄMPFLI, M. R. 
2007. Cigarette smoke impairs NK cell-dependent tumor immune surveillance. 
The Journal of Immunology, 178, 936-943. 
MAENO, T., HOUGHTON, A. M., QUINTERO, P. A., GRUMELLI, S., OWEN, C. A. 
& SHAPIRO, S. D. 2007. CD8+ T Cells are required for inflammation and 
destruction in cigarette smoke-induced emphysema in mice. J Immunol, 178, 
8090-6. 
MAHESWARAN, S., SEQUIST, L. V., NAGRATH, S., ULKUS, L., BRANNIGAN, B., 
COLLURA, C. V., INSERRA, E., DIEDERICHS, S., IAFRATE, A. J. & BELL, 
D. W. 2008. Detection of mutations in EGFR in circulating lung-cancer cells. New 
England Journal of Medicine, 359, 366-377. 
Bibliography 
 90 
MAKI, D. G. & TAMBYAH, P. A. 2001. Engineering out the risk for infection with 
urinary catheters. Emerging infectious diseases, 7, 342. 
MANZEL, L. J., SHI, L., O'SHAUGHNESSY, P. T., THORNE, P. S. & LOOK, D. C. 
2011. Inhibition by cigarette smoke of nuclear factor-κB–dependent response to 
bacteria in the airway. American journal of respiratory cell and molecular biology, 
44, 155-165. 
MARCINKIEWICZ, J., STRUS, M. & PASICH, E. 2013. Antibiotic resistance: a "dark 
side" of biofilmassociated chronic infections. Pol Arch Med Wewn, 123, 309-13. 
MASALHA, M., BOROVOK, I., SCHREIBER, R., AHARONOWITZ, Y. & COHEN, 
G. 2001. Analysis of Transcription of theStaphylococcus aureus Aerobic Class Ib 
and Anaerobic Class III Ribonucleotide Reductase Genes in Response to Oxygen. 
Journal of Bacteriology, 183, 7260-7272. 
MATHERS, C. D. & LONCAR, D. 2006. Projections of global mortality and burden of 
disease from 2002 to 2030. PLoS Med, 3, e442. 
MCCOMB, J. G., RANGANATHAN, M., LIU, X. H., PILEWSKI, J. M., RAY, P., 
WATKINS, S. C., CHOI, A. M. & LEE, J. S. 2008. CX3CL1 up-regulation is 
associated with recruitment of CX3CR1+ mononuclear phagocytes and T 
lymphocytes in the lungs during cigarette smoke-induced emphysema. The 
American journal of pathology, 173, 949-961. 
MCMILLIAN, M., LI, L., PARKER, J., PATEL, L., ZHONG, Z., GUNNETT, J., 
POWERS, W. & JOHNSON, M. 2002. An improved resazurin-based cytotoxicity 
assay for hepatic cells. Cell biology and toxicology, 18, 157-173. 
MELLMAN, I. & STEINMAN, R. M. 2001. Dendritic cells: specialized and regulated 
antigen processing machines. Cell, 106, 255-258. 
MIAN, M. F., LAUZON, N. M., STÄMPFLI, M. R., MOSSMAN, K. L. & ASHKAR, 
A. A. 2008. Impairment of human NK cell cytotoxic activity and cytokine release 
by cigarette smoke. Journal of leukocyte biology, 83, 774-784. 
MITTAL, S. K. & ROCHE, P. A. 2015. Suppression of antigen presentation by IL-10. 
Current opinion in immunology, 34, 22-27. 
Bibliography 
 91 
MODESTOU, M. A., MANZEL, L. J., EL-MAHDY, S. & LOOK, D. C. 2010. Inhibition 
of IFN-γ-dependent antiviral airway epithelial defense by cigarette smoke. 
Respiratory research, 11, 64. 
MOEINTAGHAVI, A., ARAB, H. R., REZAEE, S. A. R., NADERI, H., SHIEZADEH, 
F., SADEGHI, S. & ANVARI, N. 2017. The effects of smoking on expression of 
IL-12 and IL-1β in gingival tissues of patients with chronic periodontitis. The 
open dentistry journal, 11, 595. 
MOLANDER, A., REIT, C., DAHLEN, G. & KVIST, T. 1998. Microbiological status of 
root-filled teeth with apical periodontitis. International endodontic journal, 31, 
1-7. 
MORTAZ, E., LAZAR, Z., KOENDERMAN, L., KRANEVELD, A. D., NIJKAMP, F. 
P. & FOLKERTS, G. 2009. Cigarette smoke attenuates the production of 
cytokines by human plasmacytoid dendritic cells and enhances the release of IL-
8 in response to TLR-9 stimulation. Respiratory research, 10, 47. 
MOTZ, G. T., EPPERT, B. L., SUN, G., WESSELKAMPER, S. C., LINKE, M. J., 
DEKA, R. & BORCHERS, M. T. 2008. Persistence of lung CD8 T cell 
oligoclonal expansions upon smoking cessation in a mouse model of cigarette 
smoke-induced emphysema. J Immunol, 181, 8036-43. 
MURRAY, R. L., BRITTON, J. & LEONARDI-BEE, J. 2012. Second hand smoke 
exposure and the risk of invasive meningococcal disease in children: systematic 
review and meta-analysis. BMC public health, 12, 1062. 
MUSTAFA, O., ALTHAKAFI, S., KATTAN, S., KATTAN, M. & ALHATHAL, N. 
2016. Scrotal abscess precipitating late infection of a malleable penile prosthesis: 
the risk never evanesces. Case reports in urology, 2016. 
NAGRATH, S., SEQUIST, L. V., MAHESWARAN, S., BELL, D. W., IRIMIA, D., 
ULKUS, L., SMITH, M. R., KWAK, E. L., DIGUMARTHY, S. & 
MUZIKANSKY, A. 2007. Isolation of rare circulating tumour cells in cancer 
patients by microchip technology. Nature, 450, 1235. 
NAKAMURA, Y., MIYATA, M., OHBA, T., ANDO, T., HATSUSHIKA, K., 
SUENAGA, F., SHIMOKAWA, N., OHNUMA, Y., KATOH, R., OGAWA, H. 
& NAKAO, A. 2008. Cigarette smoke extract induces thymic stromal 
Bibliography 
 92 
lymphopoietin expression, leading to T(H)2-type immune responses and airway 
inflammation. J Allergy Clin Immunol, 122, 1208-14. 
NATSIS, N. E. & COHEN, P. R. 2018. Coagulase-negative Staphylococcus skin and soft 
tissue infections. American journal of clinical dermatology, 1-7. 
NEGISHI, M., IZUMI, Y., ALEEMUZZAMAN, S., INABA, N. & HAYAKAWA, S. 
2011. Lipopolysaccharide (LPS)-induced interferon (IFN)-gamma production by 
decidual mononuclear cells (DMNC) is interleukin (IL)-2 and IL-12 dependent. 
American journal of reproductive immunology, 65, 20-27. 
NG, A. K. & TRAVIS, L. B. 2008. Subsequent malignant neoplasms in cancer survivors. 
The Cancer Journal, 14, 429-434. 
NG, S. P., SILVERSTONE, A. E., LAI, Z. W. & ZELIKOFF, J. T. 2006. Effects of 
prenatal exposure to cigarette smoke on offspring tumor susceptibility and 
associated immune mechanisms. Toxicol Sci, 89, 135-44. 
NGKELO, A., MEJA, K., YEADON, M., ADCOCK, I. & KIRKHAM, P. A. 2012. LPS 
induced inflammatory responses in human peripheral blood mononuclear cells is 
mediated through NOX4 and G i α dependent PI-3kinase signalling. Journal of 
inflammation, 9, 1. 
NGUYEN, T. H., PARK, M. D. & OTTO, M. 2017. Host response to Staphylococcus 
epidermidis colonization and infections. Frontiers in cellular and infection 
microbiology, 7, 90. 
NUORTI, J. P., BUTLER, J. C., FARLEY, M. M., HARRISON, L. H., MCGEER, A., 
KOLCZAK, M. S. & BREIMAN, R. F. 2000. Cigarette smoking and invasive 
pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med, 
342, 681-9. 
OE, K., MIWA, M., SAKAI, Y., LEE, S., KURODA, R. & KUROSAKA, M. 2007. An 
in vitro study demonstrating that haematomas found at the site of human fractures 
contain progenitor cells with multilineage capacity. The Journal of bone and joint 
surgery. British volume, 89, 133-138. 
OFFICE OF THE SURGEON, G., OFFICE ON, S. & HEALTH 2004. Reports of the 
Surgeon General. The Health Consequences of Smoking: A Report of the Surgeon 
General. Atlanta (GA): Centers for Disease Control and Prevention (US). 
Bibliography 
 93 
OLSZEWSKI, M. B., GROOT, A. J., DASTYCH, J. & KNOL, E. F. 2007. TNF 
trafficking to human mast cell granules: mature chain-dependent endocytosis. The 
Journal of Immunology, 178, 5701-5709. 
OMORI-MIYAKE, M., YAMASHITA, M., TSUNEMI, Y., KAWASHIMA, M. & 
YAGI, J. 2014. In vitro assessment of IL-4-or IL-13-mediated changes in the 
structural components of keratinocytes in mice and humans. Journal of 
Investigative Dermatology, 134, 1342-1350. 
OPP, M., SMITH, E. & HUGHES JR, T. 1995. Interleukin-10 (cytokine synthesis 
inhibitory factor) acts in the central nervous system of rats to reduce sleep. Journal 
of neuroimmunology, 60, 165-168. 
OPSTAD, T. B., BRUSLETTO, B. S., ARNESEN, H., PETTERSEN, A. & SELJEFLOT, 
I. 2017. Cigarette smoking represses expression of cytokine IL-12 and its 
regulator miR-21—An observational study in patients with coronary artery 
disease. Immunobiology, 222, 169-175. 
ORGANIZATION, W. H. 2007. A WHO/The Union monograph on TB and tobacco 
control: joining efforts to control two related global epidemics. A WHO/the Union 
monograph on TB and tobacco control: joining efforts to control two related 
global epidemics. 
OUYANG, Y., VIRASCH, N., HAO, P., AUBREY, M. T., MUKERJEE, N., BIERER, 
B. E. & FREED, B. M. 2000. Suppression of human IL-1β, IL-2, IFN-γ, and TNF-
α production by cigarette smoke extracts. Journal of Allergy and Clinical 
Immunology, 106, 280-287. 
PACE, E., FERRARO, M., SIENA, L., MELIS, M., MONTALBANO, A. M., 
JOHNSON, M., BONSIGNORE, M. R., BONSIGNORE, G. & GJOMARKAJ, 
M. 2008. Cigarette smoke increases Toll - like receptor 4 and modifies 
lipopolysaccharide-mediated responses in airway epithelial cells. Immunology, 
124, 401-411. 
PATEL, I., SEEMUNGAL, T., WILKS, M., LLOYD-OWEN, S., DONALDSON, G. & 
WEDZICHA, J. 2002. Relationship between bacterial colonisation and the 
frequency, character, and severity of COPD exacerbations. Thorax, 57, 759-764. 
PATEL, J. D. 2005. Lung cancer in women. J Clin Oncol, 23, 3212-8. 
Bibliography 
 94 
PATEL, M. S. & STEINBERG, M. B. 2016. Smoking cessation. Annals of internal 
medicine, 164, ITC33-ITC48. 
PEREZ-WARNISHER, M. T., DE MIGUEL, M. D. P. C. & SEIJO, L. M. 2018. Tobacco 
Use Worldwide: Legislative Efforts to Curb Consumption. Annals of Global 
Health, 84. 
PEREZ-WARNISHER, M. T., DE MIGUEL, M. D. P. C. & SEIJO, L. M. 2019. Tobacco 
Use Worldwide: Legislative Efforts to Curb Consumption. Annals of Global 
Health, 85. 
PESSINA, G., PAULESU, L., CORRADESCHI, F., LUZZI, E., TANZINI, M., DI, A. 
S., MATTEUSCCI, G. & BOCCI, V. 1993. Production of tumor necrosis factor 
alpha by rat alveolar macrophages collected after acute cigarette smoking. 
Archivum immunologiae et therapiae experimentalis, 41, 343-348. 
PETERS, S. A., HUXLEY, R. R. & WOODWARD, M. 2013. Smoking as a risk factor 
for stroke in women compared with men: a systematic review and meta-analysis 
of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke, 44, 
2821-8. 
PHAYBOUTH, V., WANG, S. Z., HUTT, J. A., MCDONALD, J. D., HARROD, K. S. 
& BARRETT, E. G. 2006. Cigarette smoke suppresses Th1 cytokine production 
and increases RSV expression in a neonatal model. Am J Physiol Lung Cell Mol 
Physiol, 290, L222-31. 
PITTS, K., YOON, Y., KRUEGER, E. & MCNIVEN, M. A. 1999. The dynamin-like 
protein DLP1 is essential for normal distribution and morphology of the 
endoplasmic reticulum and mitochondria in mammalian cells. Molecular biology 
of the cell, 10, 4403-4417. 
PLIKUS, M. V., GUERRERO-JUAREZ, C. F., ITO, M., LI, Y. R., DEDHIA, P. H., 
ZHENG, Y., SHAO, M., GAY, D. L., RAMOS, R. & HSI, T.-C. 2017. 
Regeneration of fat cells from myofibroblasts during wound healing. Science, 355, 
748-752. 
PLOVIER, H., EVERARD, A., DRUART, C., DEPOMMIER, C., VAN HUL, M., 
GEURTS, L., CHILLOUX, J., OTTMAN, N., DUPARC, T. & LICHTENSTEIN, 
L. 2017. A purified membrane protein from Akkermansia muciniphila or the 
Bibliography 
 95 
pasteurized bacterium improves metabolism in obese and diabetic mice. Nature 
medicine, 23, 107. 
POSTMA, D. S. & BOEZEN, H. M. 2004. Rationale for the Dutch hypothesis: allergy 
and airway hyperresponsiveness as genetic factors and their interaction with 
environment in the development of asthma and COPD. Chest, 126, 96S-104S. 
POYRAZ, T., IDIMAN, E., UYSAL, S., IYILIKCI, L., ÖZAKBAŞ, S., COSKUNER 
POYRAZ, E. & IDIMAN, F. 2013. The cooling effect on proinflammatory 
cytokines interferon-gamma, tumor necrosis factor-alpha, and nitric oxide in 
patients with multiple sclerosis. ISRN neurology, 2013. 
PREVOST, V., SHUKER, D., BARTSCH, H., PASTORELLI, R., STILLWELL, W., 
TRUDEL, L. & TANNENBAUM, S. 1990. The determination of urinary 3-
methyladenine by immnunoaffinity chromatography-monoclonal antibody-based 
ELISA: use in human biomonitoring studies. Carcinogenesis, 11, 1747-1751. 
RAHMAN, I., VAN SCHADEWIJK, A. A., CROWTHER, A. J., HIEMSTRA, P. S., 
STOLK, J., MACNEE, W. & DE BOER, W. I. 2002. 4-Hydroxy-2-nonenal, a 
specific lipid peroxidation product, is elevated in lungs of patients with chronic 
obstructive pulmonary disease. American journal of respiratory and critical care 
medicine, 166, 490-495. 
RANGASAMY, T., CHO, C. Y., THIMMULAPPA, R. K., ZHEN, L., SRISUMA, S. S., 
KENSLER, T. W., YAMAMOTO, M., PETRACHE, I., TUDER, R. M. & 
BISWAL, S. 2004. Genetic ablation of Nrf2 enhances susceptibility to cigarette 
smoke–induced emphysema in mice. The Journal of clinical investigation, 114, 
1248-1259. 
RAO, Q., SHANG, W., HU, X. & RAO, X. 2015. Staphylococcus aureus ST121: a 
globally disseminated hypervirulent clone. Journal of medical microbiology, 64, 
1462-1473. 
REA, T. D., HECKBERT, S. R., KAPLAN, R. C., SMITH, N. L., LEMAITRE, R. N. & 
PSATY, B. M. 2002. Smoking status and risk for recurrent coronary events after 
myocardial infarction. Annals of Internal Medicine, 137, 494-500. 
REYNOLDS, P. R., KASTELER, S. D., SCHMITT, R. E. & HOIDAL, J. R. 2011. 
Receptor for advanced glycation end-products signals through Ras during tobacco 
Bibliography 
 96 
smoke–induced pulmonary inflammation. American journal of respiratory cell 
and molecular biology, 45, 411-418. 
ROBAYS, L. J., LANCKACKER, E. A., MOERLOOSE, K. B., MAES, T., BRACKE, 
K. R., BRUSSELLE, G. G., JOOS, G. F. & VERMAELEN, K. Y. 2009. 
Concomitant inhalation of cigarette smoke and aerosolized protein activates 
airway dendritic cells and induces allergic airway inflammation in a TLR-
independent way. The Journal of Immunology, 183, 2758-2766. 
ROBBINS, C. S., BAUER, C. M., VUJICIC, N., GASCHLER, G. J., LICHTY, B. D., 
BROWN, E. G. & STÄMPFLI, M. R. 2006. Cigarette smoke impacts immune 
inflammatory responses to influenza in mice. American journal of respiratory and 
critical care medicine, 174, 1342-1351. 
ROBBINS, C. S., FRANCO, F., MOUDED, M., CERNADAS, M. & SHAPIRO, S. D. 
2008. Cigarette smoke exposure impairs dendritic cell maturation and T cell 
proliferation in thoracic lymph nodes of mice. The Journal of Immunology, 180, 
6623-6628. 
ROBBINS, C. S., POULADI, M. A., FATTOUH, R., DAWE, D. E., VUJICIC, N., 
RICHARDS, C. D., JORDANA, M., INMAN, M. D. & STAMPFLI, M. R. 2005. 
Mainstream cigarette smoke exposure attenuates airway immune inflammatory 
responses to surrogate and common environmental allergens in mice, despite 
evidence of increased systemic sensitization. J Immunol, 175, 2834-42. 
ROILIDES, E., SIMITSOPOULOU, M., KATRAGKOU, A. & WALSH, T. J. 2015. 
How Biofilms Evade Host Defenses. Microbiol Spectr, 3. 
RUSSELL, R. E., THORLEY, A., CULPITT, S. V., DODD, S., DONNELLY, L. E., 
DEMATTOS, C., FITZGERALD, M. & BARNES, P. J. 2002. Alveolar 
macrophage mediated elastolysis: roles of matrix metalloproteinases, cysteine and 
serine proteases. American Journal of Physiology-Lung Cellular and Molecular 
Physiology. 
SALMON-EHR, V., RAMONT, L., GODEAU, G., BIREMBAUT, P., GUENOUNOU, 
M., BERNARD, P. & MAQUART, F.-X. 2000. Implication of interleukin-4 in 
wound healing. Laboratory investigation, 80, 1337. 
SAMET, J. M. & WIPFLI, H. L. 2010. Globe still in grip of addiction. Nature, 463, 1020. 
Bibliography 
 97 
SAXENA, A., KHOSRAVIANI, S., NOEL, S., MOHAN, D., DONNER, T. & HAMAD, 
A. R. A. 2015. Interleukin-10 paradox: A potent immunoregulatory cytokine that 
has been difficult to harness for immunotherapy. Cytokine, 74, 27-34. 
SCANLON, P. D., CONNETT, J. E., WALLER, L. A., ALTOSE, M. D., BAILEY, W. 
C., SONIA BUIST, A. & E LUNG HEALTH STUDY RESEARCH GROUP, D. 
P. T. F. T. 2000. Smoking cessation and lung function in mild-to-moderate 
chronic obstructive pulmonary disease: the Lung Health Study. American Journal 
of Respiratory and Critical Care Medicine, 161, 381-390. 
SCHRODER, K., HERTZOG, P. J., RAVASI, T. & HUME, D. A. 2004. Interferon-γ: 
an overview of signals, mechanisms and functions. Journal of leukocyte biology, 
75, 163-189. 
SEATON, A., SEATON, D. & LEITCH, A. G. 2000. Crofton and Douglas's respiratory 
diseases, Blackwell Science Oxford. 
SEO, M.-D., KANG, T. J., LEE, C. H., LEE, A.-Y. & NOH, M. 2012. HaCaT 
keratinocytes and primary epidermal keratinocytes have different transcriptional 
profiles of cornified envelope-associated genes to T helper cell cytokines. 
Biomolecules & therapeutics, 20, 171. 
SEREZANI, A. P., BOZDOGAN, G., SEHRA, S., WALSH, D., KRISHNAMURTHY, 
P., POTCHANANT, E. A. S., NALEPA, G., GOENKA, S., TURNER, M. J. & 
SPANDAU, D. F. 2017. IL-4 impairs wound healing potential in the skin by 
repressing fibronectin expression. Journal of Allergy and Clinical Immunology, 
139, 142-151. e5. 
SHAIK, S. S., DOSHI, D., BANDARI, S. R., MADUPU, P. R. & KULKARNI, S. 2016. 
Tobacco use cessation and prevention–A review. Journal of clinical and 
diagnostic research: JCDR, 10, ZE13. 
SHAN, M., CHENG, H.-F., SONG, L.-Z., ROBERTS, L., GREEN, L., HACKEN-
BITAR, J., HUH, J., BAKAEEN, F., COXSON, H. O. & STORNESS-BLISS, C. 
2009. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses 
in human emphysema. Science Translational Medicine, 1, 4ra10-4ra10. 
SKEHAN, P., STORENG, R., SCUDIERO, D., MONKS, A., MCMAHON, J., VISTICA, 
D., WARREN, J. T., BOKESCH, H., KENNEY, S. & BOYD, M. R. 1990. New 
Bibliography 
 98 
colorimetric cytotoxicity assay for anticancer-drug screening. JNCI: Journal of 
the National Cancer Institute, 82, 1107-1112. 
SLOAN, A., HUSSAIN, I., MAQSOOD, M., EREMIN, O. & EL-SHEEMY, M. 2010. 
The effects of smoking on fracture healing. The Surgeon, 8, 111-116. 
SMELTER, D. F., SATHISH, V., THOMPSON, M. A., PABELICK, C. M., VASSALLO, 
R. & PRAKASH, Y. 2010. Thymic stromal lymphopoietin in cigarette smoke-
exposed human airway smooth muscle. The Journal of Immunology, 185, 3035-
3040. 
SMITH, C. & HANSCH, C. 2000. The relative toxicity of compounds in mainstream 
cigarette smoke condensate. Food and Chemical Toxicology, 38, 637-646. 
SOLIMAN, D. M. & TWIGG, H. L., 3RD 1992. Cigarette smoking decreases bioactive 
interleukin-6 secretion by alveolar macrophages. Am J Physiol, 263, L471-8. 
SOPORI, M. 2002. Effects of cigarette smoke on the immune system. Nature Reviews 
Immunology, 2, 372. 
SOPORI, M. L. & KOZAK, W. 1998. Immunomodulatory effects of cigarette smoke. 
Journal of neuroimmunology, 83, 148-156. 
SORENSEN, L. T., FRIIS, E., JORGENSEN, T., VENNITS, B., ANDERSEN, B. R., 
RASMUSSEN, G. I. & KJAERGAARD, J. 2002. Smoking is a risk factor for 
recurrence of groin hernia. World journal of surgery, 26, 397-400. 
SPILIOPOULOU, A. I., KOLONITSIOU, F., KREVVATA, M. I., LEONTSINIDIS, M., 
WILKINSON, T. S., MACK, D. & ANASTASSIOU, E. D. 2012. Bacterial 
adhesion, intracellular survival and cytokine induction upon stimulation of 
mononuclear cells with planktonic or biofilm phase Staphylococcus epidermidis. 
FEMS microbiology letters, 330, 56-65. 
SRIRANGAN, S. & CHOY, E. H. 2010. The role of interleukin 6 in the pathophysiology 
of rheumatoid arthritis. Therapeutic advances in musculoskeletal disease, 2, 247-
256. 
STÄMPFLI, M. R. & ANDERSON, G. P. 2009. How cigarette smoke skews immune 
responses to promote infection, lung disease and cancer. Nature Reviews 
Immunology, 9, 377. 
Bibliography 
 99 
STANLEY, K. 1986. Lung cancer and tobacco--a global problem. Cancer detection and 
prevention, 9, 83-89. 
STEINGRIMSSON, S., GOTTFREDSSON, M., KRISTINSSON, K. G. & 
GUDBJARTSSON, T. 2008. Deep sternal wound infections following open heart 
surgery in Iceland. A population-based study. Scandinavian cardiovascular 
journal, 42, 208-213. 
STRIZ, I. 2017. Cytokines of the IL-1 family: recognized targets in chronic inflammation 
underrated in organ transplantations. Clin Sci (Lond), 131, 2241-2256. 
SU, W.-H., CHENG, M.-H., LEE, W.-L., TSOU, T.-S., CHANG, W.-H., CHEN, C.-S. 
& WANG, P.-H. 2010. Nonsteroidal anti-inflammatory drugs for wounds: pain 
relief or excessive scar formation? Mediators of inflammation, 2010. 
SWANN, J., COQUET, J., SMYTH, M. & GODFREY, D. 2007. CD1-restricted T cells 
and tumor immunity. T Cell Activation by Cd1 and Lipid Antigens. Springer. 
TADDESE, R., BELZER, C., AALVINK, S., DE JONGE, M. I., NAGTEGAAL, I. D., 
DUTILH, B. E. & BOLEIJ, A. 2018. Bacterial Zombies And Ghosts: Production 
Of Inactivated Gram-Positive And Gram-Negative Species With Preserved 
Cellular Morphology And Cytoplasmic Content. BioRxiv, 458158. 
TAKADA, K., KOMINE-AIZAWA, S., HIROHATA, N., TRINH, Q. D., NISHINA, A., 
KIMURA, H. & HAYAKAWA, S. 2017. Poly I: C induces collective migration 
of HaCaT keratinocytes via IL-8. BMC immunology, 18, 19. 
TALHOUT, R., SCHULZ, T., FLOREK, E., VAN BENTHEM, J., WESTER, P. & 
OPPERHUIZEN, A. 2011. Hazardous compounds in tobacco smoke. Int J 
Environ Res Public Health, 8, 613-28. 
TARASEVICIENE-STEWART, L., SCERBAVICIUS, R., CHOE, K.-H., MOORE, M., 
SULLIVAN, A., NICOLLS, M. R., FONTENOT, A. P., TUDER, R. M. & 
VOELKEL, N. F. 2005. An animal model of autoimmune emphysema. American 
journal of respiratory and critical care medicine, 171, 734-742. 
THATCHER, T. H., BENSON, R. P., PHIPPS, R. P. & SIME, P. J. 2008. High-dose but 
not low-dose mainstream cigarette smoke suppresses allergic airway 
inflammation by inhibiting T cell function. Am J Physiol Lung Cell Mol Physiol, 
295, L412-21. 
Bibliography 
 100 
TIEN, B. Y. Q., GOH, H. M. S., CHONG, K. K. L., BHADURI-TAGORE, S., HOLEC, 
S., DRESS, R., GINHOUX, F., INGERSOLL, M. A., WILLIAMS, R. B. H. & 
KLINE, K. A. 2017. Enterococcus faecalis Promotes Innate Immune Suppression 
and Polymicrobial Catheter-Associated Urinary Tract Infection. Infect Immun, 85. 
TOKAJIAN, S. 2014. New epidemiology of Staphylococcus aureus infections in the 
Middle East. Clinical Microbiology and Infection, 20, 624-628. 
TOLLERUD, D. J., CLARK, J. W., BROWN, L. M., NEULAND, C. Y., MANN, D. L., 
PANKIW-TROST, L. K., BLATTNER, W. A. & HOOVER, R. N. 1989. 
Association of cigarette smoking with decreased numbers of circulating natural 
killer cells. Am Rev Respir Dis, 139, 194-198. 
TRIMBLE, N. J., BOTELHO, F. M., BAUER, C. M., FATTOUH, R. & STAMPFLI, M. 
R. 2009. Adjuvant and anti-inflammatory properties of cigarette smoke in murine 
allergic airway inflammation. American journal of respiratory cell and molecular 
biology, 40, 38-46. 
TSAI, J., HOMA, D. M., GENTZKE, A. S., MAHONEY, M., SHARAPOVA, S. R., 
SOSNOFF, C. S., CARON, K. T., WANG, L., MELSTROM, P. C. & TRIVERS, 
K. F. 2018. Exposure to secondhand smoke among nonsmokers—United States, 
1988–2014. Morbidity and Mortality Weekly Report, 67, 1342. 
TSUCHISAKA, A., FURUMURA, M. & HASHIMOTO, T. 2014. Cytokine regulation 
during epidermal differentiation and barrier formation. Journal of investigative 
dermatology, 134, 1194-1196. 
VALAVANIDIS, A., VLACHOGIANNI, T. & FIOTAKIS, K. 2009. Tobacco smoke: 
involvement of reactive oxygen species and stable free radicals in mechanisms of 
oxidative damage, carcinogenesis and synergistic effects with other respirable 
particles. International journal of environmental research and public health, 6, 
445-462. 
VAN DER TOORN, M., SLEBOS, D. J., DE BRUIN, H. G., LEUVENINK, H. G., 
BAKKER, S. J., GANS, R. O., KOETER, G. H., VAN OOSTERHOUT, A. J. & 
KAUFFMAN, H. F. 2007. Cigarette smoke-induced blockade of the 
mitochondrial respiratory chain switches lung epithelial cell apoptosis into 
necrosis. Am J Physiol Lung Cell Mol Physiol, 292, L1211-8. 
Bibliography 
 101 
VARMA, T. K., TOLIVER-KINSKY, T. E., LIN, C. Y., KOUTROUVELIS, A. P., 
NICHOLS, J. E. & SHERWOOD, E. R. 2001. Cellular mechanisms that cause 
suppressed gamma interferon secretion in endotoxin-tolerant mice. Infection and 
immunity, 69, 5249-5263. 
VASSALLO, R., KROENING, P. R., PARAMBIL, J. & KITA, H. 2008. Nicotine and 
oxidative cigarette smoke constituents induce immune-modulatory and pro-
inflammatory dendritic cell responses. Molecular immunology, 45, 3321-3329. 
VASSALLO, R., TAMADA, K., LAU, J. S., KROENING, P. R. & CHEN, L. 2005. 
Cigarette smoke extract suppresses human dendritic cell function leading to 
preferential induction of Th-2 priming. J Immunol, 175, 2684-91. 
VERHOECKX, K., COTTER, P., LÓPEZ-EXPÓSITO, I., KLEIVELAND, C., LEA, T., 
MACKIE, A., REQUENA, T., SWIATECKA, D. & WICHERS, H. 2015. The 
impact of food bioactives on health: in vitro and ex vivo models, Springer. 
VICHAI, V. & KIRTIKARA, K. 2006. Sulforhodamine B colorimetric assay for 
cytotoxicity screening. Nature protocols, 1, 1112. 
WALLACE, L., ROBERTS-THOMPSON, L. & REICHELT, J. 2012. Deletion of 
K1/K10 does not impair epidermal stratification but affects desmosomal structure 
and nuclear integrity. J Cell Sci, 125, 1750-1758. 
WALSER, T., CUI, X., YANAGAWA, J., LEE, J. M., HEINRICH, E., LEE, G., 
SHARMA, S. & DUBINETT, S. M. 2008. Smoking and lung cancer: the role of 
inflammation. Proceedings of the American Thoracic Society, 5, 811-815. 
WALTERS, M. J., PAUL-CLARK, M. J., MCMASTER, S. K., ITO, K., ADCOCK, I. 
M. & MITCHELL, J. A. 2005. Cigarette smoke activates human monocytes by 
an oxidant-AP-1 signaling pathway: implications for steroid resistance. 
Molecular pharmacology, 68, 1343-1353. 
WANG, P.-H., HUANG, B.-S., HORNG, H.-C. & YEH, C.-C. 2017. Yi-Jen Chen. 
Journal of the Chinese Medical Association, 20, 1e8. 
WANG, T., LONG, S., ZHAO, N., WANG, Y., SUN, H., ZOU, Z., WANG, J., RAN, X. 
& SU, Y. 2016. Cell density-dependent upregulation of PDCD4 in keratinocytes 
and its implications for epidermal homeostasis and repair. International journal 
of molecular sciences, 17, 8. 
Bibliography 
 102 
WATERS, C. M. & GOLDBERG, J. B. 2019. Pseudomonas aeruginosa in cystic fibrosis: 
A chronic cheater. Proc Natl Acad Sci U S A. 
WATTERS, C., DELEON, K., TRIVEDI, U., GRISWOLD, J. A., LYTE, M., HAMPEL, 
K. J., WARGO, M. J. & RUMBAUGH, K. P. 2013. Pseudomonas aeruginosa 
biofilms perturb wound resolution and antibiotic tolerance in diabetic mice. Med 
Microbiol Immunol, 202, 131-41. 
WEN, C., TSAI, S., CHENG, T., CHAN, H., CHUNG, W. & CHEN, C. 2005. Excess 
injury mortality among smokers: a neglected tobacco hazard. Tobacco control, 14, 
i28-i32. 
WEST, R. 2017. Tobacco smoking: Health impact, prevalence, correlates and 
interventions. Psychology & health, 32, 1018-1036. 
WILSON, B. A., SALYERS, A. A., WHITT, D. D. & WINKLER, M. E. 2011. Bacterial 
pathogenesis: a molecular approach, American Society for Microbiology (ASM). 
WISPLINGHOFF, H., BISCHOFF, T., TALLENT, S. M., SEIFERT, H., WENZEL, R. 
P. & EDMOND, M. B. 2004. Nosocomial bloodstream infections in US hospitals: 
analysis of 24,179 cases from a prospective nationwide surveillance study. 
Clinical infectious diseases, 39, 309-317. 
WITSCHI, H. 2004. Carcinogenic activity of cigarette smoke gas phase and its 
modulation by beta-carotene and N-acetylcysteine. Toxicological Sciences, 84, 
81-87. 
WONG, L. S. & MARTINS - GREEN, M. 2004. Firsthand cigarette smoke alters 
fibroblast migration and survival: implications for impaired healing. Wound 
repair and regeneration, 12, 471-484. 
WOODRUFF, P. G., KOTH, L. L., YANG, Y. H., RODRIGUEZ, M. W., FAVORETO, 
S., DOLGANOV, G. M., PAQUET, A. C. & ERLE, D. J. 2005. A distinctive 
alveolar macrophage activation state induced by cigarette smoking. American 
journal of respiratory and critical care medicine, 172, 1383-1392. 
WRIGHT, V. J. 2006. Osteoporosis in men. JAAOS-Journal of the American Academy of 
Orthopaedic Surgeons, 14, 347-353. 
Bibliography 
 103 
XIE, T. T., ZENG, H., REN, X. P., WANG, N., CHEN, Z. J., ZHANG, Y. & CHEN, W. 
2019. Antibiofilm activity of three Actinomycete strains against Staphylococcus 
epidermidis. Lett Appl Microbiol, 68, 73-80. 
XING, Z., GAULDIE, J., COX, G., BAUMANN, H., JORDANA, M., LEI, X.-F. & 
ACHONG, M. K. 1998. IL-6 is an antiinflammatory cytokine required for 
controlling local or systemic acute inflammatory responses. The Journal of 
clinical investigation, 101, 311-320. 
YANG, S.-R., CHIDA, A. S., BAUTER, M. R., SHAFIQ, N., SEWERYNIAK, K., 
MAGGIRWAR, S. B., KILTY, I. & RAHMAN, I. 2006. Cigarette smoke induces 
proinflammatory cytokine release by activation of NF-κB and posttranslational 
modifications of histone deacetylase in macrophages. American Journal of 
Physiology-Lung Cellular and Molecular Physiology, 291, L46-L57. 
YANG, Y., YOO, H. M., CHOI, I., PYUN, K. H., BYUN, S. M. & HA, H. 1996. 
Interleukin 4-induced proliferation in normal human keratinocytes is associated 
with c-myc gene expression and inhibited by genistein. Journal of investigative 
dermatology, 107, 367-372. 
ZAROCOSTAS, J. 2009. Twenty four risk factors responsible for nearly half of annual 
deaths, says WHO. British Medical Journal Publishing Group. 
ZHOU, L., CHONG, M. M. & LITTMAN, D. R. 2009. Plasticity of CD4+ T cell lineage 
differentiation. Immunity, 30, 646-655. 
ZOU, J. & SHANKAR, N. 2014. Enterococcus faecalis infection activates 
phosphatidylinositol 3-kinase signaling to block apoptotic cell death in 
macrophages. Infection and immunity, 82, 5132-5142. 
ZOU, J. & SHANKAR, N. 2016. The opportunistic pathogen Enterococcus faecalis 
resists phagosome acidification and autophagy to promote intracellular survival 
in macrophages. Cellular microbiology, 18, 831-843. 
 
 
Declaration 
 104 
7. Declaration 
This work was conducted in the laboratory of Siegfried Weller Institute in Tübingen 
University for biochemistry under the direction and support of my supervisor Prof. Dr. 
Andreas Nüssler. 
 
 
I declare that all the experiments were performed by myself and all the data were 
calculated by myself.  
The MD thesis: “Influence of cigarette smoking on immune response of PBMCs to 
inactivated bacteria and on wound healing” is totally written by myself. Any sources from 
others were all quoted in the sentence and added with my own understanding, not a simple 
repetition.  
 
 
 
 
 
Tübingen, 01.08.2019 
Zi Li 
 
  
Permission 
 105 
8. Permission of quoting Figure 1 
 
Acknowledgement 
 106 
9. Acknowledgement 
At this very moment, so much appreciation needs to be expressed that there are not 
enough words that could fully convey my gratitude to those who have helped me. 
First and foremost, I cherish this precious opportunity to thank my respectful, enduring 
and benevolent supervisor Prof. Dr. Andreas Nüssler, who provides me such a treasured 
chance to study at the Eberhard Karls Universty Tübingen at the Siegfried Weller Institute 
to complete my project for Doctor of Medicine.  
In addition, I must express my genuine gratitude to my co-advisor PD Dr. Sabrina Ehnert, 
who has always been patiently offering me suggestions and answering all my questions 
both in research and in writing this thesis. 
Moreover, I also would like to thank Hanna Scheffler for giving me plenty of 
technological guidance in my migration assay experiments, and I miss the days when I 
did ELISAs with Markus Denzinger who helped me and discussed them with me. 
Besides, I am also grateful to all of my laboratory colleagues at the Siegfried Weller 
Institute who have helped me in my studies.  
Certainly, I really thank Wuhan Tongji Hospital who gives me this precious opportunity 
to study here and gives me financial support.  
Finally, I thank my parents who have always encouraged and supported me throughout 
the overseas learning stage. I hope that I could accompany them at any time in the future 
and compensate them for things I have not done during the past several years. 
  
Curriculum Vitae 
 107 
10. Curriculum Vitae 
Zi Li 
 
 
   Tübingen University                                Jul. 2018-Dec. 2019  
   Doctor in Medicine, Tübingen, Germany 
   Huazhong University of Science and Technology         Sept. 2014-Jun. 2017 
   Master in Orthopedic Surgery, Wuhan in Hubei, China 
   Huazhong University of Science and Technology         Sept. 2009-Jun. 2014 
   Bachelor in Clinical Medicine, Wuhan in Hubei, China 
   Jianli First Senior High School                        Sept. 2006-Jun.2009 
   Senior high school student, Jingzhou in Hubei, China  
   Xinjian Junior Middle School                         Sept. 2003-Jun.2006 
   Junior middle school student, Jingzhou in Hubei, China 
   Xiaqiao Primary School                              Sept. 1997-Jun.2003 
   Elementary school student, Jingzhou in Hubei, China 
    
    
Sept. 2014- Jul. 2018         Worked as an orthopedic resident 
                          Tongji Hospital affiliated to Tongji Medical College of       
                          Huazhong University of Science and Technology 
 
 
 
Education 
Clinical Experience 
Professional & Research Skills 
Curriculum Vitae 
 108 
 
 
 
 
Research Experience 
Curriculum Vitae 
 109 
 
 
One original article has been published by me with the first author's identity as follows: 
Title: 
 
 
 
 
 
 
 
Publication 
